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abstract Cancer is one of the biggest health problem for humans. Until now, there is no 
efficient therapy for most cancers. An alternative method to conventional 
cancer treatments, including chemotherapy, radiotherapy and surgery, could be 
photodynamic therapy (PDT), which combines three components: a 
photoactive drug (photosensitizer, PS), a particular type of light and oxygen. In 
PDT, the severe side effects of chemotherapy or radiotherapy are minimized.
However, as all clinical protocols, PDT still has some problems to solve. One of 
the difficulties in PDT is to find an ideal PS for the different tumors. 
Recently, nanoparticle-based delivery systems have been explored as efficient 
vehicles to deliver PSs in PDT. In particular, silica nanoparticles (SNPs) are 
attracting great attention in PDT due to their biocompatibility, large surface 
area, controllable size formation, hydrophilic surface and ability for surface 
functionalization. The possibility for tumor targeting through surface 
modification is a key to successful cancer treatment. As such, this dissertation 
describes the synthesis and characterization of novel photosensitizer-silica 
nanoparticle hybrids for controlled singlet oxygen (1O2) release in cancer PDT. 
The work is divided into three chapters in which novel nanoformulations are 
presented as third generation PSs for PDT. In the first part, S-glycoside 
porphyrins (Pors) were prepared and encapsulated into SNPs by Stöber 
method. In the next part, the same Pors were grafted on the surface of sphere-
shaped and rod-shaped mesoporous silica nanoparticles (MSNPs). Finally, 
NPs encapsulating phosphonate phthalocyanine (Pc) or covalently appended 
with Pc were prepared after slight modification of the reverse microemulsion 
method. 
These new nanomaterials show relatively homogeneous morphological 
characteristics, such as size and shape. The new nanocarriers are able to 
produce 1O2 after light irradiation and have been employed for in vitro studies 
with two human bladder cancer epithelial cell lines, HT-1376 and UM-UC-3. 
The results showed that the new nanoparticle-based systems could be 
successfully used as novel PSs in PDT of bladder cancer which is the fourth 
most commonly diagnosed cancer with the high rate of recurrence. 
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Terapia Fotodinâmica, Câncer 
resumo O cancro é um dos maiores problemas de saúde para os humanos. Até agora, 
não há terapia eficiente para a maioria dos cancros. A terapia fotodinâmica 
(PDT) tem surgido como um método alternativo aos tratamentos convencionais 
de cancro, nomeadamente a quimioterapia, radioterapia e cirurgia. A PDT 
combina três componentes: uma droga fotoativa (fotossensibilizador, PS), luz e 
oxigênio. Os efeitos secundários observados em quimioterapia ou radioterapia 
são minimizados na PDT. No entanto, como em todos os protocolos clínicos, a 
PDT apresenta também limitações, nomeadamente a utilização de um PS 
aplicável a diferentes tumores. 
Recentemente, as nanopartículas têm sido exploradas como veículos do PS a 
administrar em PDT. Em particular, as nanopartículas de sílica (SNPs) têm 
merecido uma especial atenção devido à sua biocompatibilidade, elevada área 
de superfície específica, quase monodispersidade e superfícies hidrofílicas 
com possibilidade de funcionalização química. Um aspeto crucial para um bem 
sucedido tratamento do cancro prende-se com a adequada modificação 
superficial vdas SNPs tendo o tumor como alvo. Como tal, esta dissertação 
descreve a síntese e caracterização de novos híbridos do tipo 
fotossensibilizador-nanopartículas de sílica para libertação controlada de 
oxigénio singleto (1O2) na PDT aplicada ao cancro. 
O trabalho é dividido em três capítulos que descrevem nanoformulações para 
PDT em que o PS é de terceira geração. Na primeira parte, descreve-se a 
preparação de porfirinas de S-glicosídeo (Pors) e sua encapsulação em SNPs. 
A secção seguinte descreve a ligação dessas Pors à superfície de 
nanopartículas de sílica mesoporosa (MSNPs). Finalmente, descreve-se o 
encapsulamento de fosfonato ftalocianina (Pc) em sílica e também 
nanopartículas com Pc ligada covalentemente, utilizando uma adaptação do 
método de microemulsão inversa. 
Estes novos nanomateriais apresentam características morfológicas 
relativamente uniformes, nomeadamente em termos de tamanho e forma. 
Estes sistemas apresentam capacidade para produzir 1O2 após exposição à 
luz e foram utilizados em estudos in vitro envolvendo duas linhas de células 
epiteliais de cancro da bexiga humana, HT-1376 e UM-UC-3. Os resultados 
demonstram que as SNPs podem ser usados com sucesso como novos PSs 
em PDT de cancro da bexiga, sendo este o quarto cancro diagnosticado com a 
mais alta taxa de recorrência. 
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Terapia Fotodinámica, Cáncer 
resumen En los últimos años, el cáncer es uno de los principales problemas de salud 
para el ser humano. Hasta ahora no se ha desarrollado una terapia eficiente 
para la mayoría de los tipos de cáncer. Un método alternativo a las opciones 
convencionales de tratamiento del cáncer, como la quimioterapia, la 
radioterapia y la cirugía, podría ser la terapia fotodinámica (PDT), que combina 
tres componentes: un medicamento (fotosensibilizador o sustancia 
fotosensibilizadora, PS), un tipo particular de luz y oxígeno. En PDT los efectos 
secundarios de la quimioterapia o radioterapia se minimizan. Sin embargo, 
como es habitual en los protocolos clínicos de este campo, PDT todavía tiene 
algunos problemas por resolver. Una de las dificultades en PDT es encontrar 
un PS específico para los diferentes tumores. 
Recientemente, las nanopartículas están siendo exploradas como vehículos 
para la administración de PS en PDT. Concretamente, las nanopartículas de 
sílice (SNPs) están atrayendo una gran atención en PDT debido a su 
biocompatibilidad, elevada área superficial, obtención controlada en cuanto a 
tamaño, poro y forma, superficie hidrófila y capacidad para la funcionalización 
superficial. La posibilidad de modificar la superficie del PS para dirigirse al 
tumor puede ser la clave del éxito en el tratamiento del cáncer. En base a esto, 
esta disertación describe la síntesis y caracterización de nuevos materiales 
híbridos basados en fotosensibilizadores immobilizados en nanopartículas de 
sílice para la liberación controlada de oxígeno singlete (1O2) en PDT para 
tratamiento de cáncer. El trabajo se divide en tres capítulos en los que se 
presentan nuevas nanoformulaciones como PS de tercera generación para 
PDT. En la primera parte, derivados S-glicósidos de porfirinas (Pors) fueron 
preparados y encapsulados en SNPs mediante el método de Stöber. En la 
siguiente parte, estas Pors fueron fijadas a la superficie de nanopartículas 
mesoporosas de sílice (MSNPs). Finalmente, ftalocianinas (Pc) funcionalizadas 
con grupos fosfonato fueron encapsuladas o fijadas covalentemente a NPs 
mediante ligeras modificaciones del método de microemulsión inversa. 
Estos nuevos nanomateriales tienen una distribución de tamaños uniforme y 
son regulares en tamaño y forma. Además, todos ellos son capaces de 
producir 1O2 después de la irradiación con luz. Tras su completa 
caracterización, se realizaron estudios in vitro con dos líneas de células 
epiteliales de cáncer de vejiga humana, HT-1376 y UM-UC-3. Los resultados 
mostraron que estos nuevos sistemas basados en nanopartículas podrían ser 
utilizados con éxito como nuevos PSs en PDT de cáncer de vejiga, que es el 
cuarto cáncer más comúnmente diagnosticado con alta tasa de recurrencia. 
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CHAPTER 1: Targeting cancer cells with photoactive silica 
nanoparticles 
Wioleta Borzęcka,1,2,3 Tito Trindade,2 Tomás Torres3,4 and João Tomé1,5 
1QOPNA and 2CICECO, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, 
Portugal; 3Department of Organic Chemistry, Autonoma University of Madrid, 28049 
Madrid, Spain; 4IMDEA-Nanociencia, Campus de Cantoblanco, c/Faraday 9, 28049 
Madrid, Spain; 5Centro de Química Estrutural, Departamento de Engenharia Química, 
Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, 
Portugal 
Keywords: Porphyrins, Phthalocyanines, Photosensitizers, Silica Nanoparticles, PDT, 
Cancer 
Abstract: This introduction highlights recent advances in the preparation of silica 
nanoparticles (SNPs) functionalized with porphyrins and phthalocyanines for application 
in cancer photodiagnostic and photodynamic therapy (PDT). The use of photosensitizer-
SNP formulations has emerged recently as new nanomedicines for cancer research owing 
to their unique physicochemical properties, which make them useful for photo-biomedical 
applications. In order to study their photobiological properties, diverse chemical strategies 
involving covalent and non-covalent bonding have been used to load photosensitizers in/on 
SNPs. This revision is an update of our previous published revision, covering the last 5 
years in this hot area of photoactive nanoformulations to target and to kill cancer cells. 
 
 
Chapter 1 was published in the following journal: Targeting cancer cells with photoactive 
silica nanoparticles, Borzęcka W., Trindade T., Torres T., Tomé J. P. C.; Current 
Pharmaceutical Design, 2016, 22, 6021–6038  
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Introduction 
In recent years Nanosciences has evolved as an exciting and important scientific domains, 
with interdisciplinary approaches that involve topics of chemistry, biology, physics and 
engineering, among others. However, some of the approaches that today we recognize as 
belonging to Nanosciences share well-established processes identified in Nature or in 
conventional Science. For example, many years ago humans took advantage of 
nanomaterials by using them in several contexts, including therapeutic practices. 
Nevertheless, it is unquestionable that the progress observed in this area has opened a 
number of possibilities that rely, among other factors, on engineered nanoparticles with 
unique properties and innovative instrumentation that allows exploring nanoscale 
phenomena.  
An early example on the use of nanomaterials is the well-known Lycurgus cup, a dichroic 
glass cup that can be appreciated in The British Museum (London) and that was 
manufactured during the Roman civilization. The Lycurgus cup exhibits a color (red or 
greenish) depending on the way that is illuminated, due to the presence of metal 
nanoparticles (e.g. gold and silver) used as pigments dispersed in the glass matrix. Other 
well-known examples on the use of metal nanoparticles as pigments can be appreciated by 
the great variety of colors in glass stained windows in European cathedrals from the 
Middle Ages. The optical effects exhibited by metal nanoparticles, namely those of 
colloidal gold, have been the subject of interest by Michael Faraday (1897) and Gustav 
Mie (1908), who explained scientifically these observations. Colloidal gold was also 
explored in therapeutics since early times, noteworthy it has been reported that the 
alchemist Paracelsus prescribed a gold colloid, termed as Aurum Potabile, as the elixir of 
life. Currently, gold nanoparticles form the basis of several nanomedicines, including their 
use in association with silica materials. Although there has been an unprecedented progress 
on the association of nanosciences and medicine, the above examples indicate the 
existence of old practices in this context. 
Cancer is a major public health problem for humans, being the second leading cause of 
death in developing countries, just behind the heart diseases.1 On nanomedicine, one of the 
therapies that has explored this concept is cancer PDT, an alternative method to the 
conventional cancer treatment options, including chemotherapy, radiotherapy, and 
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surgery.2-5 Chemotherapy uses drugs that can damage or kill cancerous cells but also cause 
side effects (e. g. immunodeficiency, anaemia, hair loss, organ damage). On the other hand 
in radiotherapy malignant cells are controlled or killed by ionizing radiation which is 
limited by the cumulative radiation dose and is itself painless. PDT is an emergent 
therapeutic procedure used in cancer treatment. This technique combines three 
components: drug, visible or near-infrared (NIR) light and oxygen, which on its own do 
not have any toxic effects on the biological systems. This drug, called photosensitizer (PS) 
or photosensitizing agent, when in contact with molecular oxygen and exposed to light can 
produce reactive oxygen species (ROS) that are strongly cytotoxic to the target cells.6-9 
A PS is activated by light of a particular wavelength, which determines how deeply light 
can penetrate the body. In this way, the application of PDT combine a PS, oxygen and light 
in a certain wavelength range. Most of the PSs used in cancer therapy and other tissue 
diseases are based on a tetrapyrrole structure, such as: porphyrins (Pors)10-13, chlorins14-19, 
bacteriochlorins20-22 and phthalocyanines (Pcs)23-27 (Figure 1). However, there are also 
other dyes with different molecular frameworks such as methylene blue (MB). MB is 
already a promising drug for PDT and methemoglobinemia treatments. In 
methemoglobinemia an abnormal amount of methemoglobin, a form of hemoglobin, is 
produced. Due to this disorder, hemoglobin can carry oxygen but is unable to release it 
effectively into the tissues.28 
 
Figure 1. Molecular backbone of porphyrin, chlorin, bacteriochlorin, phthalocyanine and 
methylene blue.  
An ideal PS should be a chemically pure compound, photostable and stable in water, 
should have a high absorption peak between 600 and 800 nm, should have no dark toxicity, 
and relatively rapid clearance from normal tissues and organs.29-33 Red and infrared light 
penetrate more deeply into human tissues than blue light (Figure 2). The portion of the 
4 
 
visible and infrared spectrum between 600 and 800 nm is the ideal optical window for 
PDT. Absorption of photons with wavelength longer than approximately 800 nm does not 
provide sufficient energy to excite oxygen to its singlet state and to form a sufficient 
amount of ROS. Thus, irradiation with longer wavelength has insufficient energy to initiate 
a photodynamic reaction. 
Therefore, PSs with strong absorbance in the near infrared region, such as chlorins, 
bacteriochlorins, and phthalocyanines, often improve cancer PDT results. But there are 
also many different factors which need to be taken into consideration when choosing a PS 
and the light source/type, such as: PS max absorption, disease location, size and type of 
tumour, accessibility and cost. 
 
Figure 2. Light penetration through the tissues for light of distinct wavelength range (A: 
indigo light, B: blue light, C: green light, D: red and infrared lights) 
How is PDT used to treat cancer? 
The photodynamic action or damage in cancer PDT takes place close to the intracellular 
location of the PS. The reason why this damage occurs only close to PS’s position is 
because the lifetime of singlet oxygen (1O2) in biological media is very short, 
approximately 10-320 ns. Therefore, the lifetime of 1O2 limits its diffusion to more or less 
10 to 55 nm in cells.29 This makes PDT a selective treatment with much less secondary 
effects than conventional therapies. Apart from the first mechanism where ROS directly 
kill tumor cells, there are other two cell death mechanisms. In the second mechanism, PDT 
damages the tumor-associated vascular system, leading to tumor infarction. Finally, PDT 
can activate an immune response against tumor cells. Furthermore, these three mechanisms 
can influence each other, whose relative relevance for the overall tumor response is yet to 
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be defined. Nevertheless, long term tumor control requires the combination of all those 
components.34 
Although PDT was established 20 years ago as a clinical protocol for cancer treatment, 
there are still limitations in its use as a general protocol to treat cancer. For instance, the 
light needed to activate most photosensitizers cannot pass through more than about 1 cm of 
tissue that is why PDT is usually used to treat tumors either located on (or under) the skin 
or on the lining of internal organs. Because light cannot pass far into large tumors PDT is 
also less effective in treating these tumors. As result of this ‘light penetration limitation’, 
PDT has been mostly applied in localised cancer treatments. Some of the PSs make skin 
and eyes sensitive to light after treatment. For example, porfimer sodium,35 one of the PSs 
which is already available on the market, makes the skin and eyes sensitive to light over 
approximately 6 weeks after treatment. So, there is need to study alternatives to improve 
the efficiency of PDT and eliminate such limitations, which include low effectiveness in 
treating large tumors, burns, swelling, pain, and scarring in nearby healthy tissues or a 
persistent skin photosensitization. Therefore it is crucial to improve equipment and more 
effective ways of light activation. Also it is important to develop new powerful PSs, more 
specifically to target cancer cells, and activated by light that can penetrate tissue and treat 
deep or larger tumors. In the context of all these limitations, NPs have recently emerged as 
promising vehicles for PDT giving the possibility to successfully improve cancer 
treatment.36-38 
Why to use SNPs for PDT? 
PSs have been used in PDT by employing different nanoformulations. This can improve 
PDT treatment by increasing the biocompatibility of the hydrophobic photosensitizers’ 
core and their blood circulation. Also selective accumulation in tumor tissues can be 
improved because particles of certain size tend to accumulate in tumor tissue much more 
than they do in normal tissue which is called enhanced permeability and retention effect 
(EPR).39-41 In this field, silica nanoparticles (SNPs) have emerged as promising vehicles 
for PDT owing to their potential biocompatibility, large surface area, controllable size 
formation, hydrophilic surface and ability for surface functionalization, hence the 
possibility for tumor targeting through surface modification.42 These unique physico-
chemical properties make SNPs ideal platforms for bioimaging43-48 and drug delivery 
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applications.49-51 Also a number of applications of SNPs take advantage of their properties 
as protecting shells for photoactive compounds and magnetic cores. Hence, amorphous 
silica shells can protect against chemical and biochemical degradation, release of toxic 
ions, and activation of immune response.52 SNPs could be combined with therapeutic drugs 
for chemotherapy53-55 or with PSs for cancer PDT.56-58 Both PS and chemotherapeutic drug 
can be stored in a single SNP to improve the cancer treatment.59-61 Moreover, metal core 
can be incorporated inside SNP which allows the combination of therapies60,62,63 and 
facilitates the removal and reutilization of the PS.64,65 Building a silica layer on a magnetic 
NP could enhance hyperthermia treatment66,67 and magnetic resonance image (MRI).68-70 
In order to develop better NPs for specific cancer treatment, it is crucial to acquire 
knowledge on the NPs biodistribution and cell targeting. For example, particles of a range 
size between 5-100 nm are able to penetrate the brain, but with an uptake efficiency that 
decreases exponentially by increasing size. Besides, in order to penetrate the lung, the NPs 
should be smaller than 200 nm. If the size of NPs is less than 100 nm, they can be taken up 
by Kupffer cells in liver and if NPs are bigger than 100 nm, they can cross liver fenestrae 
and target hepatocytes.71 
The discovery, in the early 1990s, of the new family of molecular sieves (M41S) 
contributed for a rapid advancement of research on mesoporous silica materials.72 In 2001, 
a MCM-41-type mesoporous silica material was first reported as a drug delivery system. 
Perez-Pariente et al.73 developed a MCM-41 materials showing capability for accepting 
and delivering organic compounds. This property is evidenced by using MCM-41 samples 
as hosts and the ibuprofen molecule as the guest. It was shown that ibuprofen occupies 
partially the MCM-41 mesopores, and it could diffuse out of them when the ibuprofen-
loaded samples were immersed into a simulated body fluid, thus leading to new studies on 
the use of SNPs for drug delivery applications.74,75 
Targeted delivery NPs can help to obtain chemical specificity to target binding sites 
presented in cancer cell.76-78 Surface modification is a promising strategy to improve the 
efficacy and safety of therapeutic agents. Usually the ligands employed for targeted 
nanocarriers are small molecules (e.g. folic acid and carbohydrates), vitamins, peptides 
(RGD), nucleic acids (aptamers), proteins, antibodies and their fragments, between 
others.76 
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Folic acid has been used as a targeting ligand for selective delivery of attached imaging 
and therapeutic agents to cancer tissues. It is easy to conjugate folic acid to both 
therapeutic and diagnostic agents and it has high affinity for folate receptors. Folate 
receptor is often overexpressed in a number of human tumours while not expressed in most 
normal tissues. Due to all of these features folic acid can be used as a highly selective 
tumor marker. It has been shown that the conjugation of folic acid to liposomes or 
polymers, facilitates tumour specific delivery of anticancer drugs.79,80 For example, Liu et 
al.81 investigated folate-conjugated fluorescent silica nanoparticles for targeting delivery to 
folate receptor-positive tumors. They demonstrated that these nanomaterials can be 
internalized into KB cells bearing folate receptors with relatively high efficiency. Yong et 
al.82 reported the synthesis of dye-loaded and folic acid conjugated organically modified 
silica NPs as targeted optical nanoprobes for in vitro and in vivo imaging. The authors have 
observed that the functionalization of FA to the NPs surface led to a strong cellular uptake 
of FA-conjugated NPs for pancreatic cancer MiaPaCa-2 cells and hepatoma SMMC-7721 
cells with FA receptors overexpressed. 
Mesoporous silica nanoparticles (MSNPs) have attracted great attention in recent years as 
drug delivery platforms, mostly because of their high biocompatibility.83,84 Tamanoi et al.85 
proved that MSNPs are not only promising material for drug delivery but they are also 
biocompatible. These authors have shown its high tolerance, by serological, hematological, 
and histopathological examination of blood samples and mouse tissues after MSNPs 
injection. Tamonoi group86 previously demonstrated that some type of MSNPs can store 
anticancer drugs, such as camptothecin (Figure 3), and can deliver them to human cancer 
cells. They successfully incorporated hydrophobic anticancer drug, camptothecin, into the 
pores of fluorescent MSNPs with the size ̴ 130 nm. Moreover, they delivered the drug into 
human cancer cells, PANC-1, AsPC-1, Capan- 1 (pancreatic), MKN45 (gastric) and 
SW480 (colon) to induce cell death. In the same research it was suggested that MSNPs 
might be used as nanocarriers to overcome limitations due to insolubility of many 
anticancer drugs. Secondly, they prepared nanocarriers via a sol–gel method incorporating 
fluorescein isothiocyanate (FITC), by a APTS linkage, for biodistribution fluorescence 
tracking experiments.85 These NPs were decorated with phosphonate groups and were 
roughly spherical in shape and 100-130 nm in diameter, with hexagonal arrays of pores. 
Later these MSNPs were decorated with folic-acid conjugates to allow their targeting to 
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cancer cells, and then camptothecin was loaded (Figure 3). In vivo studies using human 
breast cancer cell lines, MCF-7, MCF10F, and SK-BR-3, have proven the biocompatible 
attribute of MSNPs and their capability to preferentially accumulate in cancer cells and to 
deliver the loaded drugs. 
 
Figure 3. Fluorescent MSNPs modified with folic-acid-targeting ligands on the surface 
and loaded with camptothecin drug.  
In the case of amorphous SNPs, which can be also biocompatible as MSNPs, Jian et al.87 
developed a bifunctional SNPs for simultaneous in vivo imaging and PDT by encapsulating 
MB (Figure 1) in the phosphonate-terminated silica matrix 87. MBe ncapsulated 
phosphonated-terminated SNPs were synthesized using the synchronous hydrolysis of 
tetraethyl orthosilicate (TEOS) and 3-(trihydroxylsilyl)propyl methylphosphonate 
(THPMP) in water-in-oil microemulsion. In vivo studies were performed with 
subcutaneous-Hela-tumor-xenografted mice and showed that the bioeffects of SNPs on 
cancer cells and normal cells were both concentration-dependent. Which means that 
cytotoxicity is increased by increasing SNPs concentration. Furthermore, this study 
demonstrated that MB can be effectively protected by the phosphonate-terminated silica 
matrix from the dye leakage and enzymatic reduction and can effectively induce cell death. 
Azzawi et al.88 investigated the direct influence of SNPs uptake on the vasodilator 
responses of rat aortic vessels, in vitro, using SNPs (100 and 200 nm sized) and distinct 
surface attributes (positive and non-modified). Thus, monodispersed fluorescent SNPs of 
defined diameter were synthesized using a modified Stöber sol-gel method using TEOS, 
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aqueous ammonia solution, and water in absolute ethanol. First rhodamine isothiocyanate 
(RITC, Figure 4) was stirred with 3-aminopropyltrimethoxysilane (APS). Then, the 
reaction vessel was filled with nitrogen gas and mechanically stirred in the absence of 
light. Then to the mixture of ammonia, absolute ethanol, water, and TEOS, APS coupled 
with RITC was added. These SNPs presented no detrimental effect on biocompatibility 
(viability, proliferation, and differentiation) 
 
Figure 4. Rhodamine isothiocyanate (RITC). 
Preparation of silica nanoparticles 
Two main approaches have been used to prepare SNPs, one relies on the Stöber and Fink 
sol–gel method; the second one uses reverse microemulsions. In 1968 Werner Stöber and 
Arthur Fink reported the sol–gel synthesis of monodisperse solid SNPs ranging in size 
from 50 nm to 2 mm.89 This method involves the controlled hydrolysis of a silica precursor 
(e.g. TEOS) and the condensation of silica oligomers, in an alcoholic solvent (ethanol) 
using a base (ammonia) as catalyst (Figure 5).  
 
Figure 5. Stöber-Fink method (sol–gel synthesis) in which the hydrolysis and 
condensation of tetraethyl orthosilicate (TEOS) are facilitated by base in ethanol/water. 
The size of the particles can be controlled by adjusting the reaction conditions. In 1992 
Bogush et al. investigated the mechanisms behind the formation and growth of silica 
particles prepared from tetraalkoxysilanes in alcoholic solutions of water and ammonia.90 
According to them “the growth proceeds through a surface reaction-limited condensation 
of hydrolyzed monomers or small oligomers. The particle formation (or particle 
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nucleation) proceeds through an aggregation process of siloxane substructures that is 
influenced strongly by the surface potential of the silica particles and the ionic strength of 
the reaction medium”.90 The final SNP size strongly depends on the ratio between 
tetraalkoxysilanes, alcohol, water, and ammonia mixtures.42 
The reverse phase microemulsion method 
An alternative method for the synthesis of monodisperse SNPs involves the use of reverse 
microemulsions (reverse phase, or water-in-oil microemulsions, W/O, Figure 6). 
 
Figure 6. General idea of reverse phase microemulsion method in which TEOS is 
hydrolyzed at the micellar interface and enters the aqueous droplet to form a silica 
nanoparticle within the micelle.  
Reverse phase microemulsions consist of nanometer-sized water droplets stabilized by a 
surfactant in an organic phase. The micelles in the microemulsion act as nanoreactors that 
assist in controlling the kinetics of particle nucleation and growth. The size and number of 
micelles within the microemulsion can be regulated by varying the water to surfactant 
ratio. This approach works particularly well for monodispersed NPs smaller than 100 nm 
in diameter and allows the encapsulation of active molecules in the reverse micelles during 
NP formation.91 Water-in-oil microemulsions are stable systems composed of aqueous and 
organic phases, and a surfactant. It has many advantages, such as mild conditions for 
encapsulation procedures and it offers straightforward control over particle size and shape 
by simple varying the microemulsion parameters.92 
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Silica nanoparticles in PDT 
PDT with Por-SNPs 
In this area, few reviews have been published, one of them being ours.93 In here we are 
revising the last 5 years of works that have been coming out in this hot area.  
Ximing et al.94 prepared novel SNPs with controllable fluorescence intensity from 
porphyrin-bridged silsesquioxane. To study the properties of tetrakis(p-
chloroacetyloxy)phenylporphyrin incorporated in SNPs, firstly they covalently linked 
porphyrin to (3- aminopropyl)triethoxysilane (APTS) and by using the selfassembly of 
porphyrin linked covalently to silsesquioxane, incorporated porphyrin into the silica matrix 
(Figure 7). Using the same procedure, Por without covalently linked (3-aminopropyl) 
triethoxysiane was not effectively encapsulated, most probably because this Por forms 
aggregates in water.94 This procedure results in NPs with a narrow size-distributed region 
and a regular spherical structure with a size of 100 nm. Here, Por was entirely entrapped 
into SNPs due to the covalent attachment in the system and formed core-shell structures, 
which efficiently prevents aggregation, leakage and fluorescence quenching effects. This 
research gives an efficient synthetic example to a family of PS and mesoporous core-shell 
materials with excellent optical properties and good stability in aqueous solution, thus 
novel platforms for many applications. 
 
Figure 7. Silica nanoparticles doped with photostable porphyrin. 
Gao et al.95 presented a simple method to enhance photodynamic selectivity of Pors 
attached to SNPs against breast cancer cells. This straightforward system was achieved 
directly upon the interaction of cationic meso-tetrakis(N-methylpyridinium-4-yl)porphyrin 
tetratosylated (TMPyP, Figure 8) with bare SNPs. The final NPs’ size were 5–7 nm and an 
average of one TMPyP molecule was loaded per SNP. 
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Figure 8. Silica nanoparticles with adsorbed meso-tetrakis(N-methylpyridinium-4-
yl)porphyrin tetratosylated (TMPyP) on the surface.  
Morphological uniform SNPs were prepared with quaternary microemulsion method, 
leading to ~70% of the nanoparticles having diameters between 3 nm and 5 nm. Later, 
TMPyP was adsorbed onto SNPs by stirring SNPs and TMPyP at pH 8 for 48 hours under 
dark conditions. Such prepared SNPs-TMPyP were then separated from the solution by 
centrifugation, followed by washing with NaOH solution (pH 8) and drying in a vacuum 
desiccator. 
In weak acidic solutions, the adsorption of TMPyP from SNPs surface result production of 
1O2. By monitoring 1O2 luminescence at 1270 nm, quantum yields of 1O2 production were 
found to be pH-dependent, decreasing from 0.45 in a pH 3-6 to 0.08 at pH 8-9, which was 
also consistent with pH-dependent adsorption attitude of TMPyP on SNPs surface. This 
pH-controllable photosensitization makes SNPs-attached cationic Por a promising 
candidate for use in PDT. Thus, the enhanced therapeutic selectivity in the human 
adenocarcinoma breast cell line SK-BR-3 was checked at both physiological pH 7.4 and 
acidic tumor extracellular pH 6.0. The photodynamic selectivity test revealed that when the 
pH was reduced from 7.4 to 6.0, the cell viability decreased from 60% to 35% which 
means that SNPs-TMPyP exhibited pH-sensitive responses. This easy procedure gives a 
simple nanocarriers with pH-triggered therapeutic selectivity. 
He et al.96 developed organically modified silica (ORMOSIL) nanoparticles encapsulated 
with protoporphyrin IX (PpIX, Figure 9) for direct two-photon photodynamic therapy. 
PpIX, is a naturally occurring Por which can be found in haemoglobin, cytochrome c and 
other biologically relevant molecules. Similar to other Por-based PSs, PpIX has several 
disadvantages, such as low water compatibility or reduced selectivity for targeted tissues. 
ORMOSIL NPs have big pores in their matrix, which can then be loaded with either 
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hydrophilic or hydrophobic molecules. These molecules can be released from the matrix 
into selected targets. 
 
Figure 9. PpIX doped ORMOSIL nanoparticles. 
ORMOSIL NPs with PpIX were synthesized in the nonpolar core of Aerosol-OT/ dimethyl 
sulfoxide (DMSO)/water micelles. The final NPs have an average diameter of about 25 nm 
and spherical morphology with a narrow distribution of sizes. Two-photon upright 
confocal microscope confirmed their uptake in tumor cells (HeLa cells). Also, two-photon 
PDT towards HeLa cells by using PpIX doped ORMOSIL NPs showed that the death of 
HeLa cells was induced by the 1O2, which was generated by two-photon excited PpIX. 
Because of meso-porosity of ORMOSIL NPs, oxygen could easily contact the 
encapsulated PS and further be stimulated to a reactive state. And later, the ROS could be 
released from the meso-pores of ORMOSIL nanoparticles to destroy HeLa cells. These 
experiments revealed that this nanomaterial is very promising in cancer PDT. 
Ho et al.97 synthetized and studied phospholipid-functionalized mesoporous silica 
nanocarriers for selective PDT of cancer. These highly efficient, non-cytotoxic drug 
delivery platforms designed for PDT are phospholipid-capped, PpIX-loaded and 
fluorescein FITC-sensitized mesoporous silica nanocarriers derivatized with folate (Figure 
10). 
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Figure 10. Phospholipid-capped, PpIX-loaded and fluorescein FITC-sensitized 
mesoporous silica nanocarriers derivatized with folate. 
The synthesis of the final MSNPs included steps of preparation of FITC-sensitized MSPNs 
(FMSNPs), hydrophobization of FMSNPs, encapsulation of PpIX, and surface 
modification of phospholipid molecules onto the PpIX-loaded hydrophobic FMSNPs. The 
same authors98 have reported previously that phospholipid-modification of MSNPs can 
improve colloidal stability in water and also decrease nonspecific binding with proteins 
commonly presented in physiological fluids, which was also observed for these new 
nanosystems. After incorporation of the folate-ligand onto the PpIX-loaded MSNPs, it was 
confirmed that these nanocarriers offer good biocompatibility and present selective 
targeting of the folic acid (FA) receptor-overexpressed HeLa cells. In comparison to free 
PS, the NPs decreased dark toxicity and their cellular uptake was higher. Upon irradiation 
with visible light, nanocarriers generated 1O2 effectively in aqueous environments which 
was a good signal for in vitro photocytotoxicity. For the in vitro studies HeLa and A549 
cells as two cancer cell lines were chosen and it was demonstrated that neither light 
irradiation nor the MSNPs alone causes cytotoxicity. Only the combination of both was 
effective to kill the targeted cells in vitro and prevent tumor growth in vivo. This was 
proved by in vivo study of subcutaneous melanoma in nude mice inoculated with B16F10 
cells which revealed the capability for those NPs to mitigate nearly 65% of tumor growth. 
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This nanomaterial with excellent targeting ability, can be used both in fluorescence 
imaging and PDT. 
Vivero-Escoto et al.99 synthetized stimuli-responsive protoporphyrin IX silica-based 
nanoparticles for in vitro PDT. To overcome problems such as leaking, aggregation and 
self-quenching of PpIX inside of the SNPs they designed SNPs with the surface modified 
with PpIX attached through a redox-responsive linker (RR-PpIX-SNPs, Figure 11A). They 
assumed that after internalization by cancer cells, the disulfide bond would be broken 
(because of the reducing conditions present in cancer cells) and PpIX in monomeric form 
would be released and upon light exposure the PS generate 1O2, which results in cell death 
(Figure 11B). All this should eliminate aggregation of the PpIX, self-quenching and 
consequently increase the PDT efficiency. 
 
Figure 11. A) Stimuli-responsive PpIX silica-based nanoparticles; B) Redox-responsive 
release of PpIX in monomeric form under reducing conditions present in cancer cells. 
RR–PpIX–SiNPs were prepared by modifying the surface of SNPs with redox-responsive 
silyl-functionalized protoporphyrin IX ligand (RR–PpIX silane ligand, Figure 11A) via a 
grafting method. Firstly, SNPs were synthetized via a Stöber method and then previously 
prepared RR–PpIX silane ligand was grafted onto the SNPs (1:10 wt) by stirring and 
refluxing the mixture in ethanol. The final RR–PpIX–SiNPs showed sizes typically of 300 
nm in diameter and contained 85.7 μmol of PS per gram of NPs.  
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The biocompatibility and phototoxicity of these NPs were investigated in human cervical 
cancer (HeLa) cells. Cell viability measurements showed that RR–PpIX–SNPs were more 
phototoxic than a control sample which did not contain a redox-responsive linker (PpIX–
SNPs). Probably, intracellular release of PS avoids the aggregation and self-quenching. 
Confocal microscopy shows that these nanocarriers were mainly localized in lysosomes. 
Moreover, they were biocompatible in the absence of light as was proved by MTS assay. 
Release experiments demonstrated that PpIX–SNPs and RR–PpIX–SNPs are stable in the 
absence of reducing agents under normal physiological conditions. However, in the 
reducing conditions, PpIX molecules were quickly released from the RR– PpIX–SNPs 
which was demonstrated in solution and in vitro. These nanoplatforms still need 
improvement to be used in in vivo application but seems to be a very interesting alternative 
for conventional PS formulations used in PDT. 
Miao X. et al.100 prepared hollow SNPs loaded with polyhematoporphyrin (Photosan-II, 
Figure 12) and examined its effect in killing QBC939 cells. Due to the hydrophobic nature 
of Photosan- II, two problems arise: the difficult delivery in physiological environment and 
the low photophysical properties due to the aggregation of PSs, which decreased the 
production of 1O2 for PDT. In order to overcome this problem, they decided to encapsulate 
it in SNPs. 
 
Figure 12. Polyhematoporphyrin (Photosan-II) loaded hollow SNPs.  
Photosan-II loaded NPs were prepared by one-step wet chemical-based synthetic route, 
using TEOS, polyacrylic acid (or sodium polyacrylate), Photosan-II, ammonia and 
anhydrous ethanol. DLS measurements showed that the size of NPs was in the range of 25- 
90 nm. The photobiological activity of these PS-loaded NPs was evaluated on human 
cholangiocarcinoma QBC939 cells. In MTT assay, NPs and free PS at the same 
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concentration destroyed about 95.3% ± 2.0% and 55.7% ± 1.9% of QBC939 cells, 
respectively. This demonstrates that these NPs enhance the photoactivity of the PS. 
In 2013, Wen et al.101 also evaluated in vitro and in vivo cytotoxic effects of Photosan-II 
loaded hollow SNPs, but on liver cancer. NPs loaded with Photosan-II were prepared as 
indicated above (Figure 12)100. In this case, it was compared the inhibitory effects of PSs 
loaded in hollow SNPs and conventional photosensitizers on HepG2 human hepatoma cell 
proliferation. Firstly, free Photosan-II and NPs containing Photosan-II were administered 
to in vitro cultured HepG2 hepatoma cells and treated by PDT in the same conditions. 
Then both systems were evaluated in in vivo experiments on liver cancer in nude mice. 
Under the same experimental conditions NPs loaded with Photosan-II performed better 
then free PS. In both cases, in vitro and in vivo studies, hollow SNPs loaded with PS were 
more efficient than the PS alone. 
Mancin et al.102 studied targeted delivery of photosensitizers, their efficacy and selectivity 
issues revealed by multifunctional ORMOSIL nanovectors in cellular systems. PEGylated 
and non-PEGylated ORMOSIL nanoparticles were prepared by microemulsion 
condensation of VTES. To investigate the photophysical properties of the embedded dye in 
NPs, first PSs 1, 2 and 3 were synthetized (Figure 13).  
 
Figure 13. Doped, PEGylated and functional ORMOSIL NPs.  
For the PDT studies Stöber silica nanoparticles and VTES-ORMOSIL NPs (both 
PEGylated and not) doped with the alkoxysilane porphyrin derivative 1 were selected 
(Figure 13). ORMOSIL NPs containing the alkoxysilane derivatives 2 and 3 were also 
prepared (Figure 13). Photophysical properties, fluorescence lifetimes and singlet oxygen 
quantum yields of these NPs were examined. After this study the most promising were 2-
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doped ORMOSIL NPs and they were chosen with the intention of being decorated with 
functional groups for targeting cancer cells (Figure 13). As targeting agents folic acid, 
biotin, the cyclic RGD peptide and the antibody Cetuximab were chosen. 
Dye-doped, PEGylated and targeted NPs can be prepared by a simple one-pot procedure 
which allows the rapid preparation and screening of multifunctional nanosystems for PDT. 
The NPs were prepared by adding to the reaction mixture PEG derivatives. FA and biotin 
were directly linked to the NPs' amino groups via the formation of an amide bond. Thus, 
decoration with targeting agents was performed by directly adding its N-
hydroxysuccinimide ester derivatives to the reaction mixture before the purification. 
The ability of the PEGylated ORMOSIL NPs to internalize cancer and healthy cells was 
investigated. For this research A549 (human lung carcinoma cells), CCD-34Lu (human 
normal lung fibroblasts), KB (folate receptor positive cells derived via HeLa 
contamination), HeLa (human malignant cervical cells expressing low amounts of EGF 
receptor), A431 (human epidermoid carcinoma cells, expressing high amounts of EGF 
receptor) and HUVEC (human umbilical vein endothelial cells, overexpressing ανß3 
integrin) cells were selected. Next, the phototoxicity of NPs loaded with PS was 
determined in the case of both RGD- and Cetuximab-conjugated nanoparticles. Final 
results suggest the disturbance of the PEG layer with small targeting agents, but not with 
bulky antibodies. It was also concluded that dense PEGylation minimizes toxicity and 
helps the uptake by cells. 
Durand et al.103 prepared mannose-functionalized porous silica-coated magnetic 
nanoparticles for two-photon imaging or PDT of cancer cells. One of the concepts of this 
work was to prepare hybrid NPs containing a Fe3O4 magnetic core surrounded by a silica 
shell containing Por derivative and grafted targeted molecules on the surface of the NPs. 
The preparation of this nanomaterial started by forming a structured silica shell around 
magnetite NPs with the simultaneous incorporation of the PS in the silica shell. Then 
mannose moieties were grafted on the surface by covalent bond (Figure 14). Previously 
prepared aqueous solution of magnetite NPs were added to a diluted solution of TPP[pSO3-
, NH4+]3pNHCON(CH2)3Si(OEt)3 in ethanol and in the presence of NaOH. After stirring at 
70 ºC for a while, TEOS and 3-(trihydroxysilyl) propylmethylphosphonate were added and 
the resulting solution was stirred for 2 h. After workup and treated with an ethanolic 
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solution of NH4NO3 and heated at 60 ºC the suspension was collected by centrifugation 
and washed with ethanol. Based on the UV–Vis spectra, the quantity of PS encapsulated in 
NPs (Figure 14A) were 6.13 μmol/g and according to TEM measurement the size of NPs 
was 148 nm. In the following step, APTS was grafted on the surface of NPs by dispersing 
NPs in water and adding a solution of APTS in ethanol. In the last step of NPs preparation, 
mannose was grafted on the surface of NPs (Figure 14B). TEM measurements showed 
uniform-sized spherical NPs with visible metal-oxide core and silica shell. To study the 
efficacy of mannose targeting cells in PDT experiments, MDA-MB-231 breast cancer cells 
were treated with both NPs, with and without mannose functionalization. This experiment 
showed that NPs without mannose functionalization induced 26% of cell death and NPs 
functionalized with mannose induced 43% of cell death. It was proved that, the higher 
efficiency of mannose-functionalized NPs was due to an active endocytosis via mannose 
receptors. 
 
Figure 14. A) Magnetic NPs with the PS incorporated in the silica shell; B) Hybrid Fe3O4 
core-SiO2 shell nanoparticles functionalized with mannose moieties.  
Qian et al.104 demonstrated photosensitizer doped colloidal mesoporous silica nanoparticles 
for three-photon photodynamic therapy. Hence, HPPH (2-(1-hexyloxyethyl)-2-devinyl 
pyropheophorbide-a) doped MSNPs have been prepared (Figure 15), by mixing HPPH in 
DMF, and then neat VTES were stirred in Pluronic F127, 1-butanol and water. Neat APTS 
was then added when the micellar system appeared optically clear. After stirring for 24 h 
the surfactant pluronic F127 and cosurfactant 1-butanol were removed by dialysis and the 
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final NPs, with an average diameter of about 20 nm, were then filtered through a 
membrane. 
 
Figure 15. HPPH doped SNPs.  
This research combined two technologies, multiphoton microscopy and NPs-assisted PDT. 
Based on an upright confocal microscope equipped with a 1560 nm femtosecond laser, the 
direct three-photon luminescence imaging and cytotoxicity caused by PDT towards HeLa 
cells, which were uptaken by HPPH doped SNPs were proved. 
Unlike the porphyrin loaded SNP, there are few reports on the use of corroles as PS. 
Corroles are aromatic tetrapyrrolic macrocycles bearing a direct pyrrole–pyrrole linkage. 
Barata et al.105 have reported hybrid particles by covalent linking of a 
gallium(III)(pyridine) complex of 5,10,15-tris(pentafluorophenyl)corrole (GaPFC) at the 
surface of surface modified SNP. Although these systems did not show high efficiency in 
terms of singlet oxygen generation, it is one of the first examples of corrole-silica hybrid 
materials explored as an alternative for photodynamic therapy. 
PDT with Pc-SNPs 
In this area, more recently, Lei Ren et al.106 prepared multifunctional ZnPc-loaded MSNPs 
for enhancement of PDT efficacy by endolysosomal escape. Since zinc phthalocyanine 
(ZnPc, Figure 16) is hydrophobic species and undergo self-aggregation in aqueous 
solutions, which drastically reduce its photosensitizing efficiency, the preparation of ZnPc-
loaded MSNPs can help to maintain ZnPc molecules as monomers and enhance PDT 
effect. ZnPc in monomeric state has higher production of 1O2 thus acts as a better PS then 
in aggregate state.106 
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Figure 16. Poly(ethylene glycol) (PEG)- and polyethylenimine (PEI)-functionalized ZnPc-
loaded MSNPs. 
To prepare poly(ethylene glycol) (PEG)- and polyethylenimine (PEI)-functionalized ZnPc-
loaded MSNPs, first the MSNPs were synthesized using an organic template method in 
O/W phase. This procedure results in MSNPs with a specific surface area of about 632 
m2/g, with an average pore size of 3.3 nm. These NPs had a large surface area and suitable 
pore size for loading ZnPc (1.4 nm). Then, CDI (N,N′-carbonyldiimidazole) surface 
activation method was used to functionalize MSNPs with PEI and PEG. The as prepared 
MSNPs were dispersed by sonication in CDI solution and purified with ethanol by 
centrifugation. Then, the CDI activated MSNPs were dispersed in the ZnPc-saturated 
solution. The amount of ZnPc in CDI-activitated MSNPs/ZnPc (0.8 wt%) was determined 
spectrophotometrically at 670 nm.  
To modify the surface of the above NPs, CDI activated MSNPs/ZnPc were dispersed in 
water by sonication and then an aqueous solution of PEI was added. After 12 h of stirring, 
the PEI functionalized MSNPs/ZnPc (PEI-MSNPs/ZnPc) were purified by centrifugation, 
washed with water, and freeze-dried. Similar protocol was used to immobile PEG on the 
surface of these NPs. The final NPs were about 60 nm (Figure 16).  
In these nanocomposites (PEG-PEI-MSNPs/ZnPc), MSNPs acts as a nanocarrier of the 
encapsulated ZnPc, which is the PDT agent, PEI facilitates endosomal escape and PEG 
enhances biocompatibility. In vitro study with the mouse ascitic hepatoma cell line H22 
showed that the phototoxicity of the PEG-PEI-MSNPs/ZnPc is greatly enhanced compare 
with the ZnPc loaded MSNPs. Also these NPs presented high tumor specificity and 
therapeutic efficacy in vivo. After intravenous injection of PEG-PEI-MSNs/ZnPc in tumor-
bearing mice followed by light exposure, these nanoplatforms exhibited the ultra-efficient 
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passive tumor targeting and great PDT efficacy. All these attributes make the PEG- and 
PEI-functionalized MSNPs a promising multifunctional nanocarrier for PDT. 
Zhao et al.107 showed a spacer intercalated disassembly and photodynamic activity of ZnPc 
inside nanochannels of MSNPs. As was mentioned previously, ZnPc suffers severe 
aggregation in aqueous environments, thus losing its 1O2 generation efficiency. So, they 
decided to overcome this problem by loading ZnPc into the nanochannels of adamantine-
functionalized MSNPs (Figure 17). In these nanocomposites, adamantane (Ad) serves as a 
hydrophobic spacer which, functionalized inside the mesopores of MSNPs could help 
avoid the aggregation of ZnPc. Amino-substituted β-cyclodextrin (CD-2NH2) could 
enhance the dispersibility of these NPs in physiological environment, promoting NPs to be 
endocytosed by cancer cells. But also the CD-2NH2 ring could block PS inside the NPs 
preventing leakage. Additionally, the conjugation of a targeting ligand FA, with the amino 
groups of CD-2NH2 gives the possibility of targeting cancer cells. In this conditions ZnPc 
can generate cytotoxic 1O2 upon light irradiation at 675 nm in aqueous conditions. 
 
Figure 17. Schematic illustration for the ZnPc-loaded MSNP-Ad and its complex with 
CD-2NH2 (MSNPs-Ad+ZnPc+CD-2NH2-FA). 
In the beginning MSNPs-NH2 were synthesized via a co-condensation method 108. Then, 
Ad was covalently conjugated with amino groups of MSNPs-NH2, both onto the NPs 
surface and nanochannels to form MSNPs-Ad. Later, ZnPc was loaded into the 
nanochannels of MSNP-Ad and the MSNPs-Ad+ZnPc+CD-2NH2 hybrid was prepared by 
making use of strong inclusion complexation between Ad and β-cyclodextrin. The amount 
of ZnPc loaded in MSNP-Ad was determined spectrophotometrically (0.6 wt %). In the 
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end, FA was conjugated through amide bond formation between the carboxylic acid group 
on FA and the amino group on CD-2NH2. After structural characterization, the first 
photochemical studies were the photoinduced 1O2 generation capability of the hybrid. The 
promising results provide a proof-of-concept that the strategy used in immobilized PSs 
inside the nanochannels of MSNPs prevents ZnPc from aggregation. 
To examine the PDT efficiency of this new nanomaterial, the MTT cell viability assay on 
HeLa cancer cell lines was performed. Comparing MSNP-Ad+ZnPc+CD-2NH2 hybrid 
with free ZnPc in solution, using the same amount of PS in both experiments, was 
observed a more effective apoptosis effect by the hybrid after light irradiation, indicating 
high PDT efficiency. These ZnPc loaded NPs exhibit stability in aqueous solution and low 
cytotoxicity in the dark. All this together make these NPs a promising platform for the next 
generation of photodynamic therapeutics towards specific cancer treatment. 
Dennis K. P. Ng et al.109 described the preparation of amorphous SNPs of mono-
PEGylated zinc(II) phthalocyanines and their in vitro photodynamic activity. PEGylated 
ZnPc was prepared by substitution reactions of polyethylene glycol monomethyl ether 
monotosylate with 2-hydroxyphthalocyaninatozinc(II) in the presence of K2CO3 in DMF 
(Figure 18). This compound is built of hydrophilic PEG chain and the hydrophobic 
macrocyclic core thus, it is amphiphilic. Therefore these aspects enhance the cellular 
uptake and intracellular localization. 
 
Figure 18. Mono-PEGylated zinc(II) Pc NPs.  
The encapsulation of mono-PEGylated zinc(II) Pc into organically modified silica-based 
NPs was based on controlled hydrolysis of VTES in micellar media. The final 25 nm NPs 
were highly monodispersed in size and stable in aqueous media. These NPs presented high 
1O2 production efficiency so the photodynamic activity of these systems toward HepG2 
human hepatocarcinoma cells was also studied. In the conditions used for this experiment, 
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more than 97% of the cells were killed. Later, cellular uptake of these nanosystems was 
examined by confocal fluorescence microscopy. After incubation for 2 h, these NPs 
showed strong intracellular fluorescence which indicated that it was taken up effectively 
into the cells. These characteristics make these NPs promising PDT agents, because of 
their uniform size, stability in aqueous media, high 1O2 generation efficiency and high 
cellular uptake.  
Ren et al.110 presented co-enhancement of fluorescence and singlet oxygen generation by 
silica-coated gold nanorods (AuNRs) core-shell nanoparticles (Figure 19). They combined 
silica-coated AuNRs with tetra-substituted carboxyl phthalocyaninatealuminum(II) 
(AlC4Pc). In this work AlC4Pc worked in the same time as both fluorophore and PS to get 
distance-dependent metal-enhanced fluorescence (MEF) and metal-enhanced singlet 
oxygen generation phenomenon. 
 
Figure 19. Silica-coated gold nanorods core-shell nanoparticles decorated with 
tetrasubstituted carboxy AlC4Pc. 
To prepare silica-coated AuNRs core-shell structure first, AuNRs were made by well-
known seed-mediated growth process 110,111. Subsequently, to coat AuNRs with silica, 
modified Stöber method was used (Figure 19) 112. Silica layers with different thicknesses 
were obtained by adding varying amounts of TEOS. After removal of CTAB surfactant 
form AuNRs solution, NRs were re-dispersed in pure water and pH was adjusted to 10. 
Then, TEOS in methanol together with APTMS in methanol were injected to form the 
silica shell. After 24 h, the colloidal solution was centrifuged twice to remove the 
unreacted TEOS and APTMS to afforded amine-capped silica-coated AuNRs. 
The covalent binding of AlC4Pc to the surface of above NPs was performed by using EDC 
and NHS cross-linking procedure to create amide bonds between AlC4Pc and APTS. For 
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this, AlC4Pc was pre-activated by an EDC/NHS solution and then added into silica-coated 
AuNRs solution, affording AuNRs-AlC4Pc hybrid. The average length and diameter of 
AuNRs core were measured to be 46.8 ± 3.2 and 19.4 ± 1.1 nm. The uniform amorphous 
silica spacer shells had thickness from 2.1 to 28.2 nm.  
It was observed that when the AlC4Pc was bound to the surface of NRs, the fluorescence 
intensity and 1O2 generation varied with the thickness difference of silica shell. Thus, 
amorphous silica shell could serve as a spacer layer between the AuNRs and AlC4Pc to get 
an optimum fluorescence enhancement effect. Co-enhancement of fluorescence intensity 
and 1O2 production were highest when the distance between AlC4Pc and AuNRs was 10.6 
nm. These unique characteristics make the prepared AuNRs-based silica shell promising 
for MEF- fluorescence imaging and PDT. 
Zheng et al.113 synthesised magnetic, fluorescent and mesoporous core-shell-structured 
nanoparticles for simultaneous magnetic resonance imaging (MRI) and fluorescence 
imaging, cell targeting and PDT. The core of the NPs was made from a single Fe3O4 NP 
encapsulated in fluorescent dyes co-doped nonporous silica (Figure 20). This core was 
covered by ordered mesoporous silica containing PSs. To gain the targeting capacity the 
surface of NPs were functionalized with folic acid. FITC was used as fluorescence imaging 
agent which was covalently incorporated into the silica core. Their location and covalent 
bonds can isolate the dyes from the external environment and protect them from 
photobleaching. AlC4Pc was chosen as a PS, and it was covalently linked in the rigid 
porous structure of the mesoporous silica to avoid the degradation of PS in biological 
environments, and overcome their premature release. Moreover, the mesoporous structure 
of the shell allows the easy diffusion of O2 which can react with the PS for 1O2 generation. 
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Figure 20. NPs with magnetic core encapsulated in FITC co-doped nonporous silica. The 
core is covered by ordered mesoporous silica containing PSs. The surface of NPs were 
functionalized with folic acid (FA).  
Monodispersed superparamagnetic Fe3O4 NPs with an average size of 6 nm, were prepared 
using a solvothermal reaction 113,114. The NPs were then coated with nonporous silica layer 
through a reverse micelle method. To covalently incorporate FITC into these NPs, FITC 
was reacted with APTS and then co-hydrolyzed with TEOS during the reverse micelle 
encapsulation process. The resulting NPs had uniform diameter of 40 ±5 nm. Subsequent 
NPs were coated with a mesoporous silica layer by base-catalyzed hydrolysis of TEOS in 
the presence of CTAB. To covalently bind AlC4Pc in the mesoporous silica layer, AlC4Pc 
was firstly treated with APTS and then supplied together with TEOS during the coating 
process. Lastly, folic acid was covalently anchored on the surface of these NPs to 
recognize the over-expressed folate receptors presented in many cancer cells. The amount 
of AlC4Pc conjugated into the final material was about 0.51 wt%. The NPs had a uniform 
layer of mesoporous silica with a thickness of about 9 nm and uniform mesopores with an 
average pore size of 2.5 nm. Fluorescence imaging and magnetic resonance imaging were 
examined with human hepatoma cells (QGY-7703) and human hepatocytes (QSG-7701). 
Due to the introduction of fluorescence molecules it was possible to directly monitor the 
cellular uptake of the NPs by fluorescence microscopy. The surface modification with folic 
acid enhanced the delivery of PSs molecules to the targeting cancer cells that overexpress 
the folate receptor. These NPs presented much higher 1O2 production than the same 
amount of free AlC4Pc in solution which suggests that these nanovehicles act as a 
nanoreactor to facilitate the photo-oxidation reaction. In vitro studies proved that these 
nanocomposites effectively killed cancer cells through the PDT process. All these 
experiments proved the bio-applicability of these theranostic nanomaterials for MRI, 
fluorescence imaging and PDT. 
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PDT with assistance of UCNPs 
One of the biggest limitations of PDT is the small penetration depth of visible light needed 
for its activation. To overcome this problem Yong Zhang et al.37 have used mesoporous-
silica-coated upconversion fluorescent nanoparticles that in a remote-controlled mode 
converted the penetrating NIR light to visible wavelength for simultaneous activation of 
two PSs in order to enhance PDT (Figure 21). Nowadays upconversion nanoparticles 
(UCNPs), that emit high-energy photons upon excitation by low-energy NIR radiation, 
have attracted considerable attention for their application in biomedicine. One of the 
problems in using UCNPs as a PDT agent in the clinical setting is that the PSs are 
normally physically adsorbed onto their surface. This interaction is weak and has low 
attachment efficiency of the PSs to the UCNPs. The development of UCNPs coated with a 
layer of mesoporous silica shell can overcome this problem. 
 
Figure 21. UCNPs coated with a layer of amorphous silica shell and mesoporous silica 
layer encapsulating ZnPc and MC 540 photosensitizers. 
In this work mesoporous silica-coated NaYF4:Yb,Er/silica UCNPs were synthesized in a 
multistep process and then FA and PEG conjugation to the UCNPs was performed based 
on EDC/NHS method. In the end, two PSs, merocyanine 540 (MC540) and ZnPc were 
loaded into the porous of silica shell to obtain final NPs smaller than 100 nm (Figure 21). 
These UCNPs under irradiation with a 980 nm laser emitted upconversion visible 
fluorescence at two main peaks, which matched with the absorption of both PSs, MC 540 
(green at~540 nm) and ZnPc (red at ~660 nm). This feature makes these two PSs a suitable 
pair for use in conjunction with the NaYF4:Yb,Er material. Their conjugates with FA and 
polyethylene glycol were intravenously administered into tumor-bearing mice to examine 
28 
 
their targeting ability and their PDT effect. Compared to approaches using a single PS, 
dual system showed much better PDT efficacy by enhanced generation of 1O2 and reduced 
cell viability during in vivo studies with B16-F0 melanoma cells. These nanoplatforms may 
be used in the future in non-invasive deep-cancer therapy. 
Nanfeng Zheng et al.115 prepared multifunctional core-shell upconverting nanoparticles 
with AlC4Pc covalently incorporated inside the silica shells for PDT and MRI of cancer 
cells (Figure 22). 
 
Figure 22. Silica-coated lanthanide-doped UCNPs with AlC4Pc covalently incorporated in 
their interior. 
Firstly, the synthesis of lanthanide-doped UCNPs (NaGdF4:Yb/Er/NaGdF4, UCNPs) with 
an edge-length of about 22 nm were performed.115 Then, AlC4Pc photosensitizer was 
covalently bind to the silica networks of the silica-coated UCNPs. AlC4Pc was loaded into 
silica-coated UCNPs by co-hydrolysis of the AlC4Pc silanization precursor with TEOS via 
W/O microemulsion method. In this method the thickness of the silica shell (3–10 nm) was 
controlled by varying the amount of TEOS in the reaction mixture. To improve cell-uptake 
efficiency, owing to the size-dependent uptake of cells on the particle, the nanocomposite 
with the size of 38 nm was chosen for further study. The covalent coupling of PSs in the 
silica network would prevent the degradation of PS in biological environments, and 
overcome their premature release. These UCNPs encapsulated inside the silica shell were 
able to convert NIR light to strong red-light emission, which then was captured by the PS 
covalently linked. The final NPs were stable against photosensitizer leaching and highly 
efficient in 1O2 generation under NIR light. Moreover, in vitro studies with BNL 1ME 
A.7R.1 (MEAR), a mouse liver hepatoma cell line revealed that these NPs can enter cancer 
cells and successfully destroy them upon NIR irradiation. This nanosystem allowed a 
deeper light penetration than visible-light excitation. Additionally, the NPs showed good 
MRI contrast in aqueous solution and inside cells. These small size-controllable diameter 
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multifunctional NPs can be applied in versatile imaging diagnosis and as a therapy tool in 
cancer treatment. 
Huichen Guo et al.116 presented one pot facile synthesis, in vitro bioimaging and PDT of 
cancer cells with mesoporous silica-coated NaYF4 nanocrystals with encapsulated ZnPc 
(Figure 23). 
 
Figure 23. Mesoporous silica-coated UCNPs with encapsulated ZnPc.  
The first step in this study was to prepare uniform NaYF4:Yb/Er nanocrystals using the 
procedure for the high quality hexagonal phase NaYF4:Yb/Er nanocrystals which can be 
found elsewhere.116 Then, these nanocrystals were coated with mesoporous silica layer and 
finally ZnPc was loaded into the pores of the mesoporous silica by soaking the mesoporous 
silica-coated NaYF4 NPs in a solution of ZnPc in pyridine for 24 h. The final NPs were 
spherical, highly monodispersed, stable in aqueous systems and had the size of less than 50 
nm with an average pore size of 2.6 nm. Moreover, these NPs also displayed good 
biocompatibility and could be used for bio-labeling or bio-imaging and as PS carriers for 
tumor therapy. It was proved that upon excitation by a NIR laser, the NPs loaded with 
ZnPc converted NIR radiation to visible light, which later activates the PS to generate 1O2 
and destroy cancer MB49-PSA cells. This facile procedure for core-shell nanoparticles 
could be easily used in the potential applications of drug delivery and nanobiotechnology. 
Chun-Hua Yan et al.117 prepared triple-functional core-shell structured UCNPs covalently 
grafted with PS for luminescent, MRI and PDT in vitro (Figure 24). 
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Figure 24. Triple-functional core–shell structured UCNPs covalently grafted with PS. 
The 10 nm UCNPs were coated with mesoporous silica shell layer, in which PS, 
hematoporphyrin (HP) and silicon phthalocyanine dihydroxide, was covalently grafted. 
The silica shell improved the dispersibility of hydrophobic PSs in aqueous environment. 
To graft the PS onto the silica shell, carboxylic group of HP reacts with amino groups of 
APTS to form an amide bond to siloxane groups, which later hydrolyze with TEOS to form 
Si-O-Si covalent bonds. This process was not necessary in the case of Pc because it has 
two silanol hydroxyls for further hydrolysis reactions. Final NPs had 40 nm for Por-NPs 
and 35 nm for Pc-NPs. These NPs utilize NIR irradiation at 980 nm to emit luminescence 
at about 550 nm and 660 nm. The first one was used in fluorescence imaging and the other 
was absorbed by the PS molecules to generate singlet oxygen for killing cancer cells in 
PDT. Further, the Gd3+ ions with paramagnetic properties located in the core of NPs can be 
used as a contrast agent for MRI. This triple-function nanomaterial could have a bright 
future in the fields of minimally invasive therapy and rapid detection. 
Pc-NPs showed better efficiency of 1O2 generation than Por-NPs within the same 
irradiation time. Both nanomaterials exhibit excellent PDT efficiency in water solutions 
and in HeLa cells through an energy transfer process between the core and PS molecules 
under NIR laser irradiation. CaF2 is well-known to be biocompatible therefore improving 
biological safety. The nanomaterial displayed low dark cytotoxicity and NIR image in 
HeLa cells. All these unique advantages make these new multifunctional materials 
promising for applications in clinical treatment and detection. 
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PDT with chemotherapy in combination treatment 
What can enhance cancer therapy is the synergic anticancer effect of two active molecules 
such as a PS and a drug in the same nanocarrier. Having this in mind Jean-Olivier Durand 
et al.118 improved cancer therapy with MSNPs combining targeting, drug delivery and 
PDT. They designed MSNPs loaded with camptothecin (Figure 25), possessing a PS in the 
walls, and functionalized with galactose to enhance the anti-cancer activity of these 
nanocarriers. 
 
Figure 25. MSNPs covalently encapsulating PS, loaded with camptothecin and 
functionalized with galactose on the surface. 
In this research two types of NPs were prepared, MSNPs covalently encapsulating 
fluoresceine functionalized with galactose and the same NPs but with PS instead of 
fluoresceine. MSNP-FITC and MSNP-FITC-NH2 were synthesized and described,119 and 
were used for confocal localization of fluorescent NPs decorated with galactose in living 
HCT-116 cancer cells. These MSNPs, which encapsulated water soluble PSs, were 
synthesized following previously described methods.120 This procedure afforded NPs with 
a specific surface area of 728 m2/g, volume of pores of 0.50 cm3/g and pores diameter of 
2.76 nm. Dynamic light scattering showed a hydrodynamic diameter of 245 nm and 
titration (UV–Vis) gave 9.76 µmol of PS per gram of NPs. Then, previously prepared p-
[N-(2-ethoxy-3,4-dioxocyclobut-1-enyl)amino]phenyl-α-D-galactopyranoside121 was 
grafted on the surface of the MSNPs through the APTS linker to get 313 nm final NPs. In 
the end, the anticancer drug camptothecin was loaded by stirring these NPs with 
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camptothecin in DMSO. After centrifugation NPs were washed with water and dried under 
vacuum. UV–vis titrations showed that camptothecin was loaded in the MSNPs in 7.11 
µmol g−1. 
Confocal localization of fluorescent MSNPs loaded with FITC and decorated with 
galactose in living HCT-116 cancer cells indicated that these NPs were more efficiently 
internalized in comparison with unfunctionalized NPs. Which means that galactose 
functionalization is an efficient targeting of MSNPs to cancer cells. The accumulation of 
galactose-functionalized NPs in the endosomal and lysosomal compartments was mediated 
by galactose receptors present on the colorectal cancer cells. 
MSNPs functionalized with a PS and sugar and containing camptothecin combined drug 
delivery and PDT were tested on three cancer cell lines, colorectal (HCT-116), pancreatic 
(Capan-1) and breast cancer (MDA-MB-231), selected for their high invasive and 
metastatic potentials. These nanoplatforms showed a dramatic improvement of cancer cell 
death, induced 79–100% cell death, compared to individual treatments. These data provide 
the proof of principle that synergic anticancer effect of two active molecules such as a PS 
(Por) and a drug (camptothecin) in the same nanocarrier enhance cancer therapy. 
Zhuang Liu et al.122 fabricated mesoporous silica nanorods intrinsically doped with a PS, 
chlorin e6 (Ce6), and loaded with doxorubicin (DOX), a widely used anti-cancer drug 
(Figure 26). This nanomaterial was applied as a multifunctional drug carrier for 
combination therapy of cancer. During the preparation of these NPs it was observed that by 
increasing the amount of Ce6 doped inside the silica matrix, the morphology of MSNPs 
changes from spheres to rod-like shapes.  
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Figure 26. Mesoporous silica nanorods intrinsically doped with chlorin e6 and loaded with 
doxorubicin (DOX), a widely used anti-cancer drug.  
Ce6-doped mesoporous silica nanorods were prepared first by formation of amide bonds 
between Ce6 and APTS. To prepare Ce6-doped mesoporous silica nanorods firstly, Ce6 
was covalently conjugated to APTS by the formation of amide bonds. Then, nanorods were 
synthesized by co-condensation of TEOS together with different amounts of APTS-
conjugated Ce6 in the presence of aqueous ammonia and CTAB. Different from spherical 
MSNPs prepared without addition of APTS-Ce6, the obtained nanorods showed various 
morphologies from spheres to rods. By increasing the amount of APTS-Ce6 it was possible 
to synthesized four types of nanorods with average dimensions of 208/170 nm, 307/108 
nm, 311/90 nm and 340/74 nm. 
In the end, all four new materials were loaded with DOX. The most promising 
nanamaterials were 340/74 nm nanorods because of its highest Ce6 loading, faster uptake 
by cancer cells, and similar DOX loading compared with other nanorods. The Ce6 loading 
on nanocarriers was stable thanks to covalent conjugation. On the other hand, DOX 
showed pH-dependent release because it was only non-covalently adsorbed into the 
mesoporous structure. Thus, this multifunctional nanosystem can be both use in PDT 
(without the need of Ce6 release) and in chemotherapy (after DOX is released from 
nanocarriers and entered cell nuclei). 
It was observed that the nanorods with average dimensions of 340/74 nm are uptaken by 
cancer cells much faster than spherical NPs. Therefore, as a drug delivery platform for in 
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vitro and in vivo studies, these NPs were chosen. After successful combined PDT and 
chemotherapy of cancer in cellular experiments with 4T1, HeLa and 283T cells, in vivo 
animal studies were performed. Following in vivo study with Balb/c mice bearing 4T1 
tumors it was observed that combined PDT/chemotherapy is much effective than each 
individual therapy.  
Jianmei Lu et al.123 studied amphiphilic copolymer coated upconversion nanoparticles for 
near-infrared light-triggered dual anticancer treatment. Like in the previous example they 
combined action of Ce6 and DOX in new core-shell nanocomposite for controlled release 
of anticancer drugs, DOX for chemotherapy and Ce6 for PDT treatment (Figure 27). To 
prepare these NPs first 20 nm Mn2+-doped UCNPs were coated with a mesoporous silica 
layer via the hydrolysis of TEOS in a micro-emulsion system. Then, long chain 
hydrocarbonoctadecyltrimethoxysilane (C18) was attached for the self-assemble process 
combined with the amphiphilic copolymer. Later, Ce6 was grafted on the surface of silica 
shell via Ce6-(3-aminopropyl) triethoxysilane. These NPs had narrow distribution and a 
particle size of about 50 nm. In the end, the NIR light-responsive amphiphilic copolymer 
containing 9,10-dialkoxyanthracene groups was used to cover the NPs via self-assembly 
process. During the last step, DOX was introduced to the reaction mixture to load it into 
final NPs. 
 
Figure 27. UCNPs coated with a mesoporous silica layer, decorated with C18 and Ce6, 
loaded with DOX and covered by amphiphilic copolymer. 
The nanosystem worked as follow, upon irradiation with a 980 nm laser, NPs were able to 
absorb and convert the NIR light to higher-energy visible red light (660 nm). This process 
excited PS to generate 1O2 which degraded dialkoxyanthracene group in the amphiphilic 
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copolymer. As soon as copolymer was detached from the surface of the NPs, the pre-
loaded drug was released. Later, experiments demonstrated that in this system the NIR 
light-controlled chemotherapy and PDT could worked simultaneously. Like in the former 
case, in vitro and in vivo experiments with KB cells also proved that comparing NPs with 
and without DOX, the drug-loaded multifunctional NPs possessed better therapeutic 
efficacy, in synchronous NIR light triggered chemotherapy and PDT. 
Another example how to make more efficient combination of chemotherapy and PDT 
presented Li Chena et al.124 with dual pH-responsive MSNPs (Figure 28). They prepared 
NPs which can respond to the cancer extracellular and intercellular pH stimuli. On the 
surface of these NPs histidine was grafted to allow the acid sensitive PEGylated 
tetraphenylporphyrin zinc (Zn-Por-CA-PEG) behaved as a gatekeeper to prevent loaded-
drug from leaching at health tissues. This operation closed the pores of MSNPs by the 
metallo-supramolecular-coordinated interaction between Zn-Por and histidine. To 
synthetize acid sensitive PEGylated Zn-Por in the beginning, Zn-Por-CA was prepared by 
reaction between Zn-Por-NH2 and CA. Then, Zn-Por-CA was PEGylated by condensation 
between the carboxyl group of Zn-Por-CA and the hydroxyl group of PEG. PEG was used 
to enhance the biocompatibility and stability in vivo. 
 
Figure 28. Dual pH-responsive MSNPs. 
As a scaffold, MCM-41 type MSNPs with an average diameter of 140 nm were used. 
These NPs decorated with NH2 groups were synthesized according to a reference 
procedure.125 To prepare histidine modified NPs, MSNPs–NH2 were dispersed in 
anhydrous DMSO, and then BOC-histidine, EDC·HCl and NHS were added into the 
solution. After workup these NPs reacted with earlier prepared Zn-Por-CA-PEG. In the 
end, DOX was loaded by a simple dialysis technique. 
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Particular tissues of the body, eg. endosomal and lysosomal cell compartments (pH ≈ 5.5) 
and cancers and inflammatory tissues (pH ~ 6.8), have a more acidic pH than blood or 
healthy tissues (pH ~ 7.4). To explore these pH-differences, these acid sensitive conjugated 
nanosystem cis-aconitic anhydride (CA) between Zn-Por and PEG which in cancer cells 
(pH ~ 6.8) will cleave. Moreover, the surface of Zn-Por will be amino positively charged 
to promote cell internalization. Additionally, at intracellular acidic microenvironments 
(~5.3) the metallo-supramolecular-coordination will fall apart and carried drug and Zn-Por 
will be realised due to the removal of gatekeeper. The cytotoxicities of final NPs in the 
dark against HeLa and MCF-7 cells were evaluated in vitro by a standard MTT assay. 
These experiments indicated that MSNPs had good biocompatibility and no toxicity 
towards the normal cells. Moreover, compared with the single chemotherapy of DOX or 
PDT of Zn-Por in MSNPs, dual pH-responsive MSPs showed higher in vitro cytotoxicity. 
All of this together showed a great potential of this new nanomaterial in cancer treatment. 
Juan L. Vivero-Escoto et al.126 loaded MSNPs with cisplatin and aluminum chloride 
phthalocyanine (AlClPc) for combination chemotherapy and PDT (Figure 29).  
 
Figure 29. MSNPs with cisplatin and aluminum chloride phthalocyanine. 
MSNPs were synthesized by surfactant-templated approach using CTAB as the 
surfactant.127 When NPs were prepared, first AlClPc and then cisplatin molecules were 
loaded into MSNPs after stirring in DMSO. According to SEM and TEM the size of final 
NPs was 109.7 ± 13.3 nm. 
Intracellular uptake and cytotoxicity were evaluated in human cervical cancer (HeLa). 
These experiments showed that the MSNPs can be internalized in HeLa cells. Furthermore, 
after light exposure, the combination of both AlClPc and cisplatin compounds in the same 
MSNPs produce higher cytotoxic effect against HeLa cells in comparison to the control 
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MSNPs loaded with AlClPc and MSNPs loaded with cisplatin. This is another good 
example of SNPs which simultaneously carry PS and anticancer drug for combination PDT 
and chemotherapy to treat cancer. 
Double action of PDT and PTT 
Another way to improve PDT is to combine it with photothermal therapy (PTT) to get a 
double action of both treatments. Koichiro Hayashi et al.128 combined photodynamic and 
photothermal therapies using a single light source with photostable iodinated 
silica/porphyrin hybrid NPs with heavy-atom effect. The combination of PDT and PTT can 
lead to a synergistic effect. Unfortunately, in that kind of systems two light sources of 
different wavelengths usually are required, and PDT and PTT are separately carried out. It 
is difficult to focus the two light beams at the same position thus, this sequential irradiation 
complicates the treatment process. Here, it was decided to develop nanoplatforms that 
generate 1O2 and heat by irradiation with a light source of single wavelength.  
For this reason iodinated silica/Por hybrid NPs with high Por content were synthesized via 
covalent linkage by a sol-gel method using Por-containing silicon alkoxide and (3-
iodopropyl)trimethoxysilane as precursors (Figure 30). The surface of NPs were modified 
with PEG and FA. PEG was used to prevent phagocytosis by the reticuloendothelial 
system (RES) and extend the retention time in blood. Consequently, PEG promote the 
enhanced permeability and retention effect and FA increases NPs’ accumulation in tumors. 
Final NPs were spheres with rough surfaces and mean diameter of 47 ± 12 nm. 
 
Figure 30. Silica/porphyrin hybrid NPs decorated with PEG and FA. 
These NPs under LED irradiation can generate both 1O2 and heat, acting as PSs in PDT 
and as nanoheaters in PTT. Additionally, they exhibit the external heavy atom effect, 
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which considerably enhances the quantum yield for 1O2 generation and the light-to-heat 
conversion efficiency.  
For the biological study human myeloma RPMI 8226 cell line was chosen. The in vivo 
fluorescence imaging demonstrated that NPs with FA and PEG on its surface, were locally 
accumulated in the tumor cells into tumor-bearing mice. Moreover, the LED irradiation on 
the tumor area effects necrosis to the tumor tissues. The synergetic effect of both PDT and 
PTT treatment results in the inhibition of tumor growth and higher mice survival rate. This 
easy to prepare nanosystem could be employed in the PDT/PTT combination therapy 
against multiple myeloma, which is resistant to conventional chemotherapy. 
Z. X. Zhao et al.129 prepared novel mesoporous silica composite NPs of AlC4Pc and Pd 
nanosheet which were used as a dual carrier system to combine PDT with PTT (Figure 
31). This combination is possible because Pd nanosheets and PS display matched 
maximum absorptions in the range of 600–800 nm, thus the final nanomaterials can 
produce 1O2 and heat upon 660 nm single continuous wavelength laser irradiation. 
 
Figure 31. Hollow mesoporous silica composite NPs consists of AlC4Pc and Pd nanosheet.  
To prepare these materials first, water soluble PS was synthetized and covalently linked to 
a mesoporous silica network. In the next step, Pd nanosheet covered the surface of 
mesoporous silica by both coordination and electrostatic interaction. Initially SNPs were 
prepared using a modified Stöber method and then these NPs were coated with 
CTAB/SiO2 shell via base-catalyzed hydrolysis of TEOS and condensation of silica onto 
the surface of CTAB pre-coated SNPs. Simultaneously, the AlC4Pc-APTS conjugate was 
also covalently incorporated into the silica shell. To obtain NPs with hollow cores and 
penetrating pore channels, Na2CO3 was utilized to remove silica core-generating templates 
and NH4NO3 was used to remove CTAB pore-generating templates. Finally, small Pd 
nanosheets were deposited onto the surface of amino-modified NPs to get final NPs. 
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The obtained hollow mesoporous silica structure not only improved the hydrophilic 
property of the PS, but also generated 1O2 that can be easily released from the matrix. After 
confirmation of 1O2 generation by these NPs, photothermal effect of these materials under 
the irradiation of a 660 nm laser (0.5 Wcm−2), that is used for the PDT, were investigated. 
It was observed that the temperature of the NPs’ solution (200 μg of NPs in 1.0 ml of 
water) rapidly increased from 26.4 °C to 37.4 °C after 4 min of 660 nm irradiation. This 
proved the possibility of using this novel material in PDT and PTT simultaneously. The 
prepared NPs exhibited good biocompatibility and were easily up taken by cancer cells. In 
vitro results with HeLa cells showed that the cell-killing efficacy by using these NPs 
together with PDT and PTT was higher than PDT or PTT individual. 
Conclusions 
Considerable efforts have been made toward the research and development of 
nanoplatforms for cancer photodiagnostic and photodynamic therapy. Among the 
nanoparticle platforms, SNPs show particular promise. In this review, we highlighted the 
major research advances involving cancer photodiagnostic and photodynamic therapy 
based on PS-SNPs. We summarized the recent use of Por and Pc in PDT, but also the 
application of PS-SNPs in PDT with assistance of UCNPs, PDT with chemotherapy in 
combination treatment, and double action of PDT and PTT. Overall, the research advances 
in PS-SNPs delivery systems are exciting and hold great potential for future PDT 
applications. 
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CHAPTER 2: Encapsulation of glycosylated porphyrins in silica 
nanoparticles for photodynamic therapy in vitro 
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Abstract: In this study, we report the preparation, characterization and in vitro studies of 
amorphous silica nanoparticles encapsulating porphyrins (Pors). S-glycoside porphyrins 
were prepared and encapsulated into silica nanoparticles (SNPs) by Stöber method. These 
new materials were fully characterized and their in vitro properties were examined in two 
human bladder cancer cell lines, HT-1376 and UM-UC-3. The results shows that these new 
nanoformulations could be successfully used as novel photosensitizers (PSs) for 
photodynamic therapy (PDT). 
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Introduction 
Cancer is a major public health problem for humans, being the second leading cause of 
death in developing countries, just behind the heart diseases.130 Although we made 
improvements in healthcare, still more people have cancer today than ever before. 
According to trends in the lifetime risk of developing cancer in Great Britain, the biggest 
risk factor for most cancers is just getting older.131 Up to now, to treat cancer we use 
surgery, chemotherapy, radiotherapy, and PDT. Unfortunately, these treatments for some 
patients are not efficient. Among the others, PDT is a promising therapeutic procedure 
used in cancer treatment which combines three components: drug, visible or NIR lights and 
oxygen. By its own these units do not have any toxic effects on the biological systems. 
They become strongly cytotoxic to the target cells only when they produce reactive oxygen 
species (ROS) which take place when the drug, called PS or photosensitizing agent is in 
contact with molecular oxygen under specific light irradiation. 132-135 Despite the fact that 
PDT was approved by Food and Drug Admnistration (FDA) 20 years ago as a clinical 
protocol for cancer treatment, the method still have limitations to use it as a general 
protocol to treat any type of cancer.  
Thus, there is still need to study alternatives to improve the efficiency of PDT and 
eliminate its limitations, such as: low effectiveness in treating large tumors, burns, 
swelling, pain, and scarring in nearby healthy tissues or a persistent skin 
photosensitization. For that it is crucial to improve equipment and the delivery of the 
activating light. Also, it is important to develop new powerful PSs, which specifically 
target cancer cells, and activated by light that can penetrate tissue and treat large tumors. In 
the context of all limitations, NPs have recently emerged as promising vehicles for PDT 
giving the possibility to successfully improve cancer treatment.38,136,137 
Most of the PSs that are used in cancer therapy and other tissue diseases are based on a 
tetrapyrrole structure, such as: porphyrins (Pors),10,138,139 chlorins,140-143 
bacteriochlorins,144-146 and phthalocyanines (Pcs).147-150 
Using PSs in PDT as different nanoformulations can improve the treatment by increasing 
the biocompatibility of most of the hydrophobic PSs’ and their blood circulation. Also 
selective accumulation in tumor tissues can be improved thanks to enhanced permeability 
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and retention effect (EPR).39,40,151 Among others nanomaterials, silica nanoparticles (SNPs) 
have emerged as promising vehicles for PDT owing to their biocompatibility, large surface 
area, controllable size formation, hydrophilic surface and ability for surface 
functionalization, hence the possibility for tumor targeting through surface modification.42 
Moreover, amorphous silica shells can protect against chemical and biochemical 
degradation, release of toxic ions, and activation of immune response.152 Already there are 
same nanoparticle-based drug delivery platforms which were approved by FDA and others 
under clinical trials.153-155 
One of the main goals to advanced PDT is to design drugs which specifically can target the 
tumor cells with rapid cellular uptake but do not damage the healthy ones. In this field 
SNPs arrived as an outstanding platforms to covalently and non-covalently immobilize PS 
outside or inside them. Recent studies demonstrated that using SNPs combined with Pors 
could eliminate aggregation of the Pors, low water compatibility or reduced selectivity for 
targeted tissues and consequently increase the PDT efficiency.93,156 The pioneering work in 
this field appeared in 2003 when Yan et al.157 embedded meta-tetra(hydroxyphenyl)-
chlorin into silica nanoparticle platforms and showed that it could generate singlet oxygen 
(1O2) while the PS effect is maintained. Moreover, the authors have shown that the 1O2 
production by the SNPs is higher than the one from the free PS. From that time scientist 
put a lot of effort to enhance PDT with PS-SNPs. 
For instance, Gao et al.95 in a simple method enhanced photodynamic selectivity of Pors 
adsorbed onto SNPs against breast cancer cells. In the same year, He et al.96 developed 
organically modified silica (ORMOSIL) nanoparticles encapsulated with protoporphyrin 
IX (PpIX) for direct two-photon PDT. In this research ORMOSIL nanoparticles were able 
to successfully destroy HeLa cells. Ho et al.97 also used PpIX with mesoporous silica 
nanocarriers for selective PDT of cancer. These highly efficient, non-cytotoxic drug 
delivery platforms designed for PDT were phospholipid-capped, PpIX-loaded and 
fluorescein FITC-sensitized mesoporous silica nanocarriers derivatized with folate. These 
complex SNPs were effective to kill targeted HeLa and A549 cells in vitro and prevent 
further tumor growth. Miao X. et al.100 were able to overcome hydrophobic nature of 
Photosan-II by loading it into hollow SNPs. By this they eliminated the difficulties with 
the delivery in physiological environment and the low photophysical properties due to the 
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aggregation of PSs, which decreased the production of 1O2 for PDT. These NPs enhance 
the photoactivity of the PS against QBC939 cells. Later, Wen et al.101 proved that these 
NPs in in vitro and in vivo experiment on liver cancer in nude mice were more efficient 
than the PS alone. Qian et al.104 went a little bit further and developed Por (HPPH) doped 
colloidal mesoporous silica nanoparticles for three-photon photodynamic therapy. The 
cytotoxicity of PDT towards HeLa cells, which were uptaken by HPPH doped SNPs were 
proved.  
For cancer treatment applications, an ideal PS should be a chemically pure compound with 
good photostability and water solubility, should have a high absorption peak between 600 
and 800 nm (red to deep red), should have no dark toxicity, and relatively rapid clearance 
from normal tissues and organs.158-161 In this work 5,10,15,20-tetrakis(4-1’-thio-glucosyl-
2,3,5,6-tetrafluorophenyl) porphyrin (Glu-Por, PS 1) and 5,10,15,20-Tetrakis(4-1’-thio-
galactosyl-2,3,5,6-tetrafluorophenyl) porphyrin (Gal-Por, PS 2) were chosen as PSs 
(Figure 1). These Pors were chosen as PSs platforms because there are a number of reports 
on the potential of glycosylated porphyrins as PDT agents.162-166 In our research it was 
decided to use Pors with S-glycoside bonds rather than O-glycoside because drugs bearing 
saccharides with O-glycoside linkages generally have short half-lives because this bond is 
readily hydrolyzed by a variety of enzymatic and nonenzymatic acid/base reactions.167 It is 
known that aggregation of the PS decreases the efficiency of 1O2 generation. Thus, we 
decided to deliver PSs inside cancer cells into nanovehicles which could also enhance 
stability of these PSs in the aqueous media. Hence, PSs were non-covalently encapsulated 
into amorphous silica matrix, and then these nanomaterials were studied on cancer PDT. 
 
Figure 1. Structures of Glu-Por and Gal-Por used as free and encapsulated PSs. 
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Results and discussion 
Synthesis of PSs 
Porphyrins PS 1 and PS 2 were synthesized according to literature procedures present 
elsewhere.162-166 By using the nucleophilic substitution of the p-fluorine of the 
corresponding free-base porphyrin 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin 
(TPPF20) with acetyl 2,3,4,6-tetra-O-acetyl-1-thio-D-glucopyranoside or acetyl 2,3,4,6-
tetra-O-acetyl-1-thio-D-galactopyranoside were obtained the corresponding protected 
carbohydrate porphyrins. Applying simple click type synthesis these Pors bearing four 
carbohydrate moieties, conjugated via S-glycoside bond were obtained in very high yields. 
Final deprotection of the carbohydrate moieties using alkaline hydrolysis afforded the final 
S-glycoside porphyrins PS 1 and PS 2.  
Preparation of NPs and their PS-NP hybrids 
SNPs and their Por-NP nanoformulations were prepared by Stöber method in which the 
hydrolysis and condensation of tetraethyl orthosilicate (TEOS) is facilitated by base in 
ethanol and water (Figure 2).168 
 
Figure 2. Schematic preparation of PSs encapsulated into SNPs. 
To get high 1O2 generation it is crucial to encapsulate as much as possible of PSs inside 
NPs and to keep or improve the photophysical properties of the PSs after encapsulation. 
Therefore, firstly the conditions of NPs’ preparation were optimized by varying the amount 
of base, TEOS and PS (Table 1, 2, 3). Compound PS 1 was chosen as the model to 
optimize reactions. Generally, in 15 mL falcon tube PS was dissolved in EtOH and then 
NH4OH was added (total volume of this mixture was 6.250 mL). The mixture was 
sonicated for 5 min and TEOS dissolved in EtOH was added (total volume of this mixture 
was 1.250 mL). The reaction was incubated for 24 h at 25 °C under continuous agitation 
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(250 rpm) in laboratory incubator shaker (IKA KS 4000 i control) in horizontal position. 
After that time NPs were isolated by centrifugation (15 mL falcon tubes, 6000 rpm, 30 
min) and washed 4 times with EtOH. The final NPs were dried at room temperature. 
PSs encapsulation optimization studies  
Keeping the amount of PS and TEOS constants, three reactions with different amounts of 
base were performed to determine the amount of encapsulated PS versus the amount of 
base (Table 1). In this case 5 mg of PS 1 (2.977 µmol) were dissolved in EtOH and then 
NH4OH was added. The mixture was sonicated for 5 min and 83.7 µL of TEOS (0.375 
mmol) dissolved in EtOH was added. After 24 h reaction NPs were washed and dried at 
room temperature. 
NP NH4OH 
[µL] 
[mol] 
 
PS inside 
final NPs 
[mg] 
[µmol] 
Total 
amount 
of final 
NPs 
[mg] 
mg of PS/ 
mg of final 
NPs *100 
[%] 
Size of 
final NPs 
[nm] 
NP 1 187.5 
0.0012 
- - - - 
NP 2 375 
0.0024 
1.59 
0.95 
20.0 7.95 58.4 
± 6.5 
NP 3 750 
0.0048 
1.36 
0.81 
24.0 5.67 266.6 
± 24.4 
Table 1. Detailed experimental data showing how amount of encapsulated PS 1 depends 
on the amount of base.  
From these results it is clear that higher concentrations of NH4OH, give a smaller amount 
of encapsulated PS 1 into NPs. However, too low concentration of base unable even the 
formation of NPs (NP 1). The concentration of base also influences the size of NPs. After 
increasing twice the concentration of NH4OH, the size of NPs increased almost 5 times 
(NP 2 versus NP 3). For the further synthesis, 0.0024 mol of NH4OH was used. 
Keeping the amounts of PS and base constants, the dependence on amount of encapsulated 
PS from amount of TEOS were determined. For this, 5 mg of PS 1 (2.977 µmol) was 
dissolved in EtOH and then 375 µL of NH4OH (0.0024 mmol) was added. The mixture 
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was sonicated for 5 min and TEOS dissolved in EtOH was added (Table 2). After 24 h 
reaction NPs were washed and dried at room temperature. 
NP TEOS 
[µL] 
[mmol] 
 
PS inside 
final NPs 
[mg] 
[µmol] 
Total 
amount 
of final 
NPs 
[mg] 
mg of PS/ 
mg of final 
NPs *100 
[%] 
Size of 
final 
NPs 
[nm] 
NP 2 83.7 
0.375 
1.59 
0.95 
20 7.95 58.4 
± 6.5 
NP 4 500 
2.239 
1.7 
1.01 
134.6 1.27 57.5 
± 10.7 
Table 2. Detailed experimental data showing how amount of encapsulated PS depends on 
amount of TEOS. 
It was observed that the decrease of TEOS in the reaction medium by almost six times, 
increases the concentration of PS in final NPs by 6.3 times. Thus, the amount of TEOS was 
kept as 83.7 µL for the next studies. 
Then, we determined how amount of encapsulated PS depends on amount of PS in the 
reaction mixture (keeping the amounts of TEOS and base constants). For this, PS 1 was 
dissolved in EtOH and then 375 µL of NH4OH (0.0024 mmol) was added. The mixture 
was sonicated for 5 min and 83.7 µL of TEOS (0.375 mmol) dissolved in EtOH was added 
(Table 3). After 24 h reaction NPs were washed and dried at room temperature. 
NP PS 
[mg] 
[µmol] 
PS inside final 
NPs 
[mg] 
[µmol] 
Total 
amount of 
final NPs 
[mg] 
mg of PS/ 
mg of final 
NPs *100 
[%] 
Size of final 
NPs 
[nm] 
NP 5 2.5 
1.489 
0.6713 
0.4 
19.7 3.41 48.1 
± 4.6 
NP 2 5.0 
2.977 
1.59 
0.95 
20 7.95 58.4 
± 6.5 
NP 6 20.0 
11.909 
6.7 
3.989 
25.5 26.27 104.1 
± 6.2 
NP 7 50.0 
29.77 
11.2 
6.66 
23.0 48.7 197.3 
± 29.0 
Table 3. Detailed experimental data showing how amount of encapsulated PS depends on 
amount of starting PS. 
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As it is shown in above table (Table 3), the higher the concentration of PS in reaction 
mixture, the more effective is encapsulation of PS into NPs. Moreover, the size of NPs is 
changing with the same tendency. This is probably due to the fact that when the amount of 
PS was increased in the reaction medium, silica forms bigger pores and NPs become 
bigger. 
Selected PS-NPs formulation protocol  
The most successful results were obtained with the preparation of NP 7 and, consequently, 
NPs encapsulating compound PS 2 (NP 8, Table 4) were prepared according to the same 
procedure. In both cases the amount of encapsulating PS were almost the same. The same 
protocol was used to synthetize silica nanoparticles in the absence of PS (SNP) for further 
comparison and characterization (for details, please go to the SI). 
NP PS 1 
[mg] 
[µmol] 
PS 2 
[mg] 
[µmol] 
PS inside 
final NPs 
[mg] 
[µmol] 
Total 
amount 
of final 
NPs 
[mg] 
mg of PS/ 
mg of final 
NPs *100 
[%] 
µmol of 
PS/ mg 
of final 
NPs 
Size of 
NPs 
[nm] 
NP 7 50.0 
29.77 
- 11.2 
6.66 
23.0 48.7 0.289 197.3 
± 29.0 
NP 8 - 50.0 
29.77 
10.2 
6.07 
28.2 36.0 0.215 128.3 
± 22.2 
Table 4. Detailed experimental data showing differences between encapsulation of PS 1 
(NP 7) and PS 2 (NP 8). 
SNPs and PS-NPs characterization 
The selected NPs were morphologicaly and chemicaly characterized by several image and 
spectroscopic techniques. For details, please go to the SI. 
The average size of all NPs was measured by transmission electron microscopy (TEM, 
Figure SI 6-8). For final materials, NP 7 and NP 8 dynamic light scattering (DLS) was 
also used to determine their size distribution (Figure SI 9, 10). The particle size 
distribution was measured after drying the sample (TEM) and in dispersion in water 
(DLS). The difference in particle sizes measured by TEM (NP 7, 197.3 ± 29.0 nm; NP 8, 
128.3 ± 22.2 nm) and DLS (NP 7, 233.5 nm; NP 8, 133.2 nm) showed the common 
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difference between the mean hydrodynamic diameter (measured by DLS) and the size 
(measured by TEM). Typically the hydrodynamic diameter obtained by DLS is larger than 
the size gathered by TEM. These NPs have uniform size distribution and are regular in 
terms of the size and shape. 
Among other parameters, NPs’ interactions with cancer cells depends on NPs’ size which 
influence its active and passive cellular internalization. Since cell-NP interactions are 
modulated by size of NPs hence the size of nanodrug can determine the therapeutic 
targeting.169 Presented NPs have very good size for passive targeting to tumor tissues. 
Compare with healthy cells, tumor cells have poor lymphatic drainage and leaky 
vasculature. Because of that particles ranging from 10 to 500 nm accumulate inside tumor 
cells and lymphatic filtration allows them to stay there. In contrary, very often much 
smaller ordinary drugs cannot remain in tumors because they return to the circulation by 
diffusion process.170,171 
The UV-Vis absorption spectra of NP 7 and NP 8 were collected after dispersing, 
respectively, 0.535 and 0.510 mg of them in 3mL of distilled water (Figure SI 13). It is 
clear that both show the typical spectra of a free base Por, with the Soret band at 403 nm 
(NP 7) and 407 nm (NP 8). 
The EDS spectra show the chemical composition of NP 7 and NP 8, where a small 
percentage of sulphur must be related to the thio-carbohydrate moieties of the Pors (Figure 
SI 11, 12). PS 1, PS 2, SNP and the corresponding NP 7 and NP 8 were also analysed by 
FT-IR (Figure SI 14). The spectra of both NPs formulations show some of the features of 
the porphyrins (PS 1 and PS 2) and the solely silica nanoparticles (SNP). 
The amount of encapsulated PS inside NPs was calculated by UV-Vis spectrophotometry. 
The final NPs were washed with EtOH until no typical Soret and Q bands were observed in 
the rinse solvent. NP 7 (0.289 µmol/mg) have slightly higher concentration of PS per mg 
of final material than NP 8 (0.215 µmol/mg). 
Singlet oxygen generation study 
Singlet oxygen (1O2) was determined by an indirect chemical method using 1,3-
diphenylisobenzofuran (DPBF) as 1O2 quencher (for details, please go to the SI). The 1O2 
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was determined for both nanoformulations (NP 7 and NP 8) and its corresponding PSs (PS 
1 and PS 2) (Figure 3). The free PS 1 and PS 2 were tested at concentrations of 0.5 µM. 
NPs composed of PS 1 and PS 2 were tested at concentrations of PS: 12.6 µM (NP 7) and 
1.6 µM (NP 8). Both free PSs oxidized DPBF in the same way. In spite of the different 
amount of PS inside NPs and the different size of these nanoformulations, DPBF kinetic 
decay was similar in the two nanoformulations. From this study we can observe that 0.131 
mg of NP 7 could produce the same amount of 1O2 as 0.022 mg of NP 8. Which means 
that NP 8 are 6 times more efficient in terms of 1O2 generation. Although NP 8 (128.3 ± 
22.2 nm) are smaller than NP 7 (197.3 ± 29.0 nm) and have slightly lower amount of PS 
per mg of NPs (Table 4), these NPs produce higher amount of 1O2. This could be due to 
the fact that in case of smaller NPs oxygen can penetrate better their pores and 1O2 has 
shorter way to go out from nanoformulation than in bigger NPs. Thus, NP 8 are more 
effective in1O2  production than NP 7 while corresponding free Pors (PS 1 and PS 2) are 
producing the same amount of 1O2 under the equal experimental conditions. 
  
Figure 3. 1O2 generation by PS 1, PS 2 and its corresponding NPs (NP 7 and NP 8) were 
each point represents the mean of at least three independent experiments, and has a 
standard deviation lower than 3%. 
In vitro studies 
In vitro studies were carried out into two human bladder cancer cell lines, HT-1376 and 
UM-UC-3. These cell lines are suitable in vitro cancer models for the evaluation of new 
glyco-porphyrinoids, since they express the glyco-binding proteins - glucose transporter 
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(GLUT1) and galactose-binding protein (galectin-1) - in different levels.148 Previous 
studies have demonstrated that these two proteins have a key role on the uptake and further 
phototoxicity of galactodendritic PSs.148,172-174 We have previously reported that UM-UC-3 
and HT-1376 bladder cancer cells have high levels of the galactose-binding proteins, 
galectin-1 and GLUT1.148 
Cellular uptake of PSs and its nanoformulations 
Preliminary uptake studies were performed for glucosylated PS 1 and galactosylated PS 2 
(Figure 4). Bladder cancer cells were incubated with increasing concentrations of PS (0, 
2.5, 5 and 10 µM prepared in PBS, maximum 0.5% DMSO v/v) for 4 h in the darkness. 
Fluorescence spectroscopy studies demonstrated that PS 1 accumulation was higher in HT-
1376 than in UM-UC-3 cancer cells. On the other hand, the uptake of PS 2 was higher in 
UM-UC-3 than in HT-1376 cancer cells. 
 
Figure 4. Intracellular uptake of PS 1 and PS 2 (0-10 µM in PBS) by UM-UC-3 and HT-
1376 bladder cancer cells. Cells were incubated with PS for 4 h and uptake was determined 
by fluorescence spectroscopy. Data are means ± s.e.m. of at least three independent 
experiments performed in triplicates. 
Next, the uptake of NP 7 and NP 8 was evaluated by fluorescence spectroscopy and 
fluorescence microscopy (Figures 5 and 6) after incubating UM-UC-3 and HT-1376 
bladder cancer cells in dark with different concentrations of the new NPs. 
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Figure 5. Cellular uptake of NP 7 and NP 8. UM-UC-3 and HT-1376 bladder cancer cells 
were incubated with NP 7 (0-0.010 mg/mL, 0-2.89 µM of PS 1 in RPMI medium) and NP 
8 (0-0.010 mg/mL, 0-2.15 µM of PS 2 in RPMI medium) overnight. Data are means ± 
s.e.m. of at least three independent experiments performed in triplicates. 
Preliminary studies demonstrated that the uptake of both NP 7 and NP 8 (for 
concentrations ranging from 0 to 0.010 mg/mL) was negligible when cells where incubated 
with NPs for at least 4 h (data not shown). Further studies were performed by incubating 
cancer cells with PS nanoformulations overnight. When the cells were incubated overnight 
with RPMI medium containing NPs solutions there was uptake dependent on the 
concentration of the NPs and cell line. Interestingly, uptake of PS 1 and PS 2 performed 
with overnight incubation (PS solutions prepared in cell culture medium) was lower (data 
not shown) when compared with the uptake of 4 h (PS solutions prepared in PBS buffer). 
The uptake of NP 7 was higher in HT-1376 cells (which contain high levels of GLUT1 
protein) when compared with UM-UC-3 cancer cells (Figure 5). On the other hand, NP 8 
uptake was higher in UM-UC-3 cells (which contain high levels of galectin-1 protein) than 
in HT-1376 cancer cells. Considering the levels of galectin-1 and GLUT1 proteins, the 
uptake of NP 7 is higher in HT-1376 cells because these NPs contain Por bearing glucose 
moieties. On the contrary, the higher uptake of NP 8 in UM-UC-3 cancer cells was 
observed due to the presence of Por bearing galactose moieties in the pores of these 
nanoformulations. 
Further studies performed by fluorescence microscopy (Figure 6) demonstrated a strong 
fluorescence of NP 7 and NP 8 in HT-1376 and UM-UC-3 bladder cancer cells, 
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respectively, incubated overnight with 0.010 mg/mL of NP formulations (2.89 µM of PS 1 
in case of NP 7 and 2.15 µM of PS 2 for NP 8). 
 
Figure 6. Representative fluorescence images of UM-UC-3 and HT-1376 bladder cancer 
cells after overnight incubation with NP 7 (red, 0.010 mg/mL, 2.89 µM of PS 1) or NP 8 
(red, 0.010 mg/mL, 2.15 µM of PS 2 ) in darkness and cell nucleus stained with DAPI 
(blue). Scale bars, 20 µm. 
Dark toxicity and phototoxicity 
Toxicity of PS 1, PS 2, NP 7 and NP 8 in UM-UC-3 and HT-1376 bladder cancer cells in 
the dark was evaluated using the well-known MTT assay (Figures SI 16 and 17). This 
colorimetric assay determines the cell metabolic activity, by assessing the ability of living 
bladder cancer cells to reduce yellow 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT), to a purple formazan. After overnight incubation of cancer 
cells (in dark) with NPs (0-0.010 mg/mL in RPMI medium) or 4 h incubation with PSs (0-
10 µM in PBS), none of the PSs or new NPs induced dark toxicity in cancer cells (Figures 
SI 16 and 17). Moreover during 1O2 generation studies we observed that NPs are very 
much stable in the solution of DMF:H2O (9:1, by volume) in which all experiments were 
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held (Figures SI 4 and 5). However, during biological experiments slow release of PS 
form the silica matrix was detected after 4 h and 18 h incubation in PBS buffer or RPMI 
medium (Figure SI 15). Higher release in case of NP 8 was noted than in NP 7. 
After confirming the uptake and non-dark toxicity of PSs and their new NP formulations in 
UM-UC-3 and HT-1376 bladder cancer cells, their toxicity after light irradiation was 
equally evaluated using the MTT assay (Figures 7 and 8). UM-UC-3 and HT-1376 bladder 
cancer cells were incubated for 4 h with PSs (0-10 µM in PBS) or overnight with NPs (NP 
7: 0-0.010 mg/mL, 0-2.89 µM of PS 1 and NP 8: 0-0.010 mg/mL, 0-2.15 µM of PS 2) and 
then irradiated with an optical fiber emitting white light for 40 min (12 mW/cm2). No 
cytotoxicity was observed in the untreated (cells incubated in the absence of PSs or NPs) 
sham irradiated cells.  
 
Figure 7. Phototoxicity of PS 1 and PS 2 (0-10 µM in PBS) determined 24 h after PDT 
treatment using the MTT assay. The percentage of cytotoxicity was calculated relatively to 
control cells (cells incubated with PBS and then irradiated). Data are means ± s.e.m. of at 
least three independent experiments performed in triplicates. 
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Figure 8. Phototoxicity of NP 7 (0-0.010 mg/mL, 0-2.89 µM of PS 1) and NP 8 (0-0.010 
mg/mL, 0-2.15 µM of PS 2) determined 24 h after PDT treatment using the MTT assay. 
The percentage of cytotoxicity was calculated relatively to control cells (cells incubated 
with RPMI medium and then irradiated). Data are means ± s.e.m. of at least three 
independent experiments performed in triplicates.  
Both PSs and NPs induced phototoxicity in UM-UC-3 and HT-1376 bladder cancer cells in 
a concentration- and cell line-dependent manner. However, in case of NPs the 
phototoxicity much more depends on cell line type than in case of PSs (Figure 7 and 
Figure 8). NP 7 led to a significantly higher phototoxicity on HT-1376 cells compared to 
UM-UC-3 cells (Figure 8). The phototoxicity of NP 8 was higher in UM-UC-3 than in 
HT-1376 bladder cancer cells (Figure 8). Taking into account the levels of galectin-1 and 
GLUT1 proteins, the phototoxicity of NP 7 is higher in HT-1376 cells because the uptake 
of these NPs was higher due to the presence of Por bearing glucose moieties. All the same, 
the higher phototoxicity of NP 8 in UM-UC-3 cancer cells was due to their higher uptake 
by these cells because of Por bearing glucose moieties. SNPs without PSs do not induced 
phototoxicity in UM-UC-3 and HT-1376 bladder cancer cells (data not shown). 
Phototoxicity was higher with NP formulations than with PS (Figures 7-9). From the 
below figure it is clear that these new nanomaterials are more efficient in PDT than 
corresponding free Pors (Figure 9). NP 7 with 2.89 µM of PS 1 were able to destroy 
almost the same amount of HT-1376 cells as 10 µM of free PS 1. Likewise NP 8 with 2.15 
µM of PS 2 were able to damage almost equal amount of UM-UC-3 cells as 10 µM of free 
PS 2. Thus, these NPs are around 3-5 times more effective in photodynamic treatment than 
their free Pors. 
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Figure 9. Phototoxicity of PS 1 (2.5 µM, 10 µM), PS 2 (2.5 µM, 10 µM), NP 7 (2.89 µM 
of PS 1) and NP 8 (2.15 µM of PS 2) determined 24 h after PDT treatment using the MTT 
assay. The percentage of cytotoxicity was calculated relatively to control cells (cells 
incubated with RPMI medium and then irradiated). Data are means ± s.e.m. of at least 
three independent experiments performed in triplicates. 
The role of cytotoxic ROS generated after PDT with 0.010 mg/mL of NP 7 (2.89 µM of 
PS 1) and NP 8 (2.15 µM of PS 2) was evaluated using sodium azide, histidine175 and 
cysteine176 as ROS quenchers. When PDT experiments were performed with cells in the 
presence of non-toxic concentrations of ROS quenchers, there was reduction on the 
phototoxicity induced by the new NPs. Data show that 1O2 should have a high effect on the 
phototoxicity induced by NP 7 or NP 8, since phototoxicity was highly reduced when PDT 
experiments were performed with 1O2 quenchers (sodium azide and histidine). 
 
Figure 9. Phototoxicity after PDT with NP 7 (0.010 mg/mL, 2.89 µM of PS 1) and NP 8 
(0.010 mg/mL, 2.15 µM of PS 2) in the presence of 50 nM of ROS quenchers (sodium 
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azide, histidine and cysteine) in HT-1376 and UM-UC-3 cells. Cytotoxicity was assessed 
24 h after treatment using the MTT assay. The percentage of cytotoxicity was calculated 
relatively to control cells (untreated cells). Data are means ± s.e.m. of at least three 
independent experiments performed in triplicates. 
Conclusions 
In summary, two types of new PS-loaded silica nanoparticles were successfully prepared 
after modification and optimization of well-known Stöber method. Both novel materials 
were able to produce 1O2 hence in vitro studies with two human bladder cancer cell lines, 
HT-1376 and UM-UC-3, were performed. Despite slightly lower efficiency in terms of 
singlet oxygen generation compered to non-immobilized PSs, the nanocarriers offer an 
alternative route to develop new platforms for PDT. Overall, these NPs presented 3-5 times 
higher therapeutic efficacy in vitro compering with corresponding free PSs. In the 
presented work, we demonstrated that S-glycoside Pors encapsulated into silica matrix by 
straightforward Stöber method were more efficient in in vitro PDT against two human 
bladder cancer cell lines, HT-1376 and UM-UC-3, than non-encapsulated PSs. 
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Supplementary Information 
Encapsulation of glycosylated porphyrins in silica nanoparticlesfor photodynamic 
therapy in vitro 
Experimental section 
General methods 
Absorption spectra were recorded using a Shimadzu UV-2501-PC. FT-IR spectra were 
recorded in KBr pellets using GRASEBY SPECAC. The irradiation system used to 
determine the production of 1O2 and the phototoxicity during in vitro experiments was a 
Lumacare source, model LC-122, consisting on a 250 W halogen lamp coupled to an 
optical fiber (with a cutoff filter for wavelengths <540 nm). The radiation power was 
measured with a potentiometer bright Spectra Physics, model 407A and the sensor of the 
same brand, model 407A-2. The dynamic light scattering (DLS) measurements were taken 
by Zetasizer Nano ZS from Malvern Instruments. Transmission electron microscopy 
(TEM) images were obtained using a Hitachi H-9000 transmission electron microscope 
operatingat an acceleration voltage of 300 kV and JEOL 2200FS transmission electron 
microscope operating at an acceleration voltage of 200 kV. 
All reagents were obtained from commercial sources and were used without further 
purification steps. Reverse phase column chromatography was carried out on Waters Sep-
Pak C18 35 cm3 cartridges. Analytical thin layer chromatography (TLC) was carried out on 
pre-coated silica gel sheets (Merck, 60, 0.2 mm). 
Preparation of NPs 
In a 15 mL falcon tube 50 mg of PS 1 or PS 2 (29.77 µmol) was dissolved in 5.875 mL of 
EtOH and then 0.375 mL of 25% NH4OH (2.4 mmol) was added. The mixture was 
sonicated for 5 min and 83.7 µL of TEOS (0.375 mmol) in 1166.0 mL of EtOH was added. 
The reaction was incubated for 24 h at 25 °C under continuous agitation (250 rpm) in 
laboratory incubator shaker (IKA KS 4000 i control) in horizontal position. After that time 
NPs were isolated by centrifugation (15 mL falcon tubes, 6000 rpm, 30 min) and washed 
with EtOH. The final NPs were dried at room temperature. 
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The same method was used to synthetize silica nanoparticles in the absence of PS with the 
average size of 86.1 ± 10.3 nm (named as SNP). 
Singlet oxygen generation study 
Singlet oxygen (1O2) was determined by a chemical method using 1,3-
diphenylisobenzofuran (DPBF). DPBF has an absorption maximum at 415 nm, thus it is 
possible to follow the ability of the NPs to generate 1O2 by measuring the DPBF absorption 
decay, at this wavelength. The solutions were irradiated at RT and under magnetic stirring, 
with optical fiber (with a cutoff filter for wavelengths <540 nm) at a fluence rate of 10 
mW/cm2. 
 
Figure SI 1. Reaction of DPBF with 1O2. 
PS 1 (0.5 μM), PS 2 (0.5 μM), NP 7 (0.131 mg, 12.6 μM of PS 1) or NP 8 (0.022 mg, 1.6 
μM of PS 2) were placed into 3 mL cuvette which contained solution of DMF:H2O (9:1, 
by volume). Then, DPBF (50 μM) in solution of DMF:H2O was added (total volume in 
cuvette 3 mL). The breakdown of DPBF was monitored by measuring the decrease in 
absorbance at 415 nm at pre-established irradiation intervals. The results were expressed 
by plotting the DPBF depletion against the irradiation time. The depletion of DPBF was 
calculated as follows: DPBF depletion = Abs1/Abs0. Abs0 and Abs1 are the absorbance 
values at 415 nm before and after irradiation, respectively. 
Stability and photostability of PS-NPs during singlet oxygen generation study 
Stability and photostability studies were carried out in the same conditions of irradiation of 
the singlet oxygen studies. Each point represents the mean of at least three independent 
experiments, and has a standard deviation lower than 3%. Nanoparticles were stable during 
singlet oxygen study. 
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Figure SI 2. Stability of SNPs during singlet oxygen generation study. 
 
Figure SI 3. Stability of DPBF during singlet oxygen generation study. 
 
Figure SI 4. Stability of NP 7 during singlet oxygen generation study. 
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Figure SI 5. Stability of NP 8 during singlet oxygen generation study. 
Characterization of NPs 
TEM 
NP 1  NP 2  
NP 3  NP 4  
NP 5  NP 6  
Figure SI 6. TEM images of NP 1-NP 6. 
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NP 7  NP 8  
Figure SI 7. TEM images of final NP 7 and NP 8. 
 
Figure SI 8. TEM image of SNPs without PS. 
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DLS 
 
Figure SI 9. DLS size distribution of NP 7 in water. 
 
 
Figure SI 10. DLS size distribution of NP 8 in water. 
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EDS 
 
NP 7.spx Date:27-08-2015 18:14:01 HV:30.0kV Puls th.:4.70kcps  
Spectrum: NP 7.spx 
 
Element  Series  unn. C norm. C Atom. C Error (3 Sigma) 
[wt.%]  [wt.%]  [at.%]          [wt.%] 
------------------------------------------------------- 
Oxygen  K-series  41.70   49.39   50.21           15.75 
Carbon  K-series  22.35   26.47   35.85           10.29 
Silicon K-series  20.01   23.70   13.72            2.75 
Sulfur  K-series   0.37    0.43    0.22            0.13 
------------------------------------------------------- 
          Total:  84.42  100.00  100.00 
Figure SI 11. EDS of NP 7. 
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NP 8.spx Date:27-08-2015 18:10:23 HV:30.0kV Puls th.:3.83kcps 
Spectrum: NP 8.spx 
 
Element   Series  unn. C norm. C Atom. C Error (3 Sigma) 
[wt.%]  [wt.%]  [at.%]          [wt.%] 
-------------------------------------------------------- 
Oxygen   K-series  56.15   49.49   49.70           20.76 
Carbon   K-series  29.40   25.91   34.67           13.04 
Silicon  K-series  20.37   17.95   10.27            2.80 
Fluorine K-series   6.66    5.87    4.97            3.67 
Sulfur   K-series   0.88    0.77    0.39            0.19 
-------------------------------------------------------- 
           Total: 113.47  100.00  100.00 
Figure SI 12. EDS of NP 8. 
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UV-Vis 
 
Figure SI 13. UV-Vis spectra of NP 7 and NP 8. UV-Vis absorption spectra were 
collected after dispersion of 0.535 mg of NP 7 in 3mL of distilled water and 0.510 mg of 
NP 8 in 3 mL of distilled water. 
FT-IR  
 
Figure SI 14. FT-IR spectra of PS 1, PS 2, NP 7, NP 8 and SNP. FT-IR spectra were 
recorded in KBr pellets. 
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In vitro assays 
Cells culture 
Human bladder cancer cell lines UM-UC-3 and HT-1376 derived from high-grade 
transitional cell carcinoma were obtained from the American Type Culture Collection 
(ATCC®, Manassas, VA, USA). Cells were cultured in Roswell Park Memorial Institute 
(RPMI)-1640 medium (Sigma) supplemented with 2 g.L-1 sodium bicarbonate (Sigma), 2 
mM L-glutamine (Sigma), 10% (v/v) of heat-inactivated Fetal Bovine Serum (FBS; Life 
Technologies, Carlsbad, CA, USA) and antibiotic/antimicotic containing 100 units.mL-1 
penicillin, 100 µg.mL-1 streptomycin and 0.25 µg.mL-1 amphotericin B (Sigma). UM-
UC-3 and HT-1376 cells were seeded at a density of 1.5 x 104 in 96-well culture plates 
(Orange Scientific, Braine-l'Alleud, Belgium). 24 hours after plating, cells were overnight 
incubated with different concentrations of NPs (0-0.010 mg/mL in medium) in the dark. 
Cellular uptake of NPs 
After incubation with NPs in the dark, UM-UC-3 and HT-1376 cells were washed with 
PBS buffer and mechanically scrapped in 1% (m/v) sodium dodecyl sulfate (SDS; Sigma) 
in PBS buffer at pH 7.0. NPs intracellular concentration was determined by 
spectrofluorimetry using a microplate reader (Synergy HT, Biotek, Winooski, VT, USA) 
with the excitation filter (set at 360±40 nm) and emission filter (645±40 nm). Results were 
normalized for protein concentration (determined by bicinchoninic acid reagent; Pierce, 
Rockford, IL, USA). 
Microscopic evaluation 
UM-UC-3 and HT-1376 bladder cancer cells were left to grown on coated glass coverslips 
with poly-L-lysine (Sigma). After 24 h cells were incubated with 0.010 mg/mL of NPs 
overnight, at 37 ºC. Then, cells were fixed with 4% paraformaldehyde (PFA; Merck, 
Darmstadt, Germany) for 10 min at RT. In the end, the samples were rinsed in PBS, and 
mounted in VectaSHIELD mounting medium containing 4´,6-diamidino-2-phenylindole 
(DAPI; Vector Laboratories, CA, Burlingame) for visualization under a confocal 
microscope (LSM 510, Carl Zeiss, Gottingen, Germany). For DAPI detection, specimen 
was excited at 405 nm and light emitted was collected between 430-500 nm. 
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PDT treatments on cells 
Photodynamic irradiation was carried out in fresh culture medium, in the absence of NPs, 
covering UM-UC-3 and HT-1376 cell monolayers with RPMI medium and exposing them 
to white light delivered by the illumination system LC-122 LumaCare at 12 mW/cm-2 for 
40 min. As a control, sham-irradiated cells were used. These cells were kept in the dark for 
the same durations and under the same conditions as the irradiated cells. In all trials, 
triplicate wells were settled under each experimental condition, and each experiment was 
repeated at least three times. 
MTT assay 
MTT assay was used to determine cell metabolic activity after NPs incubation in the dark, 
irradiation, or both after 24 h. This colorimetric assay is measuring the ability of bladder 
cancer cells to reduce yellow 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide (MTT, Sigma), to a purple formazan on a microplate reader (Synergy HT). The 
results are expressed in percentage of control (i.e. optical density of formazan from cells 
not exposed to NPs).  
Redox quenching studies 
Photodynamic treatment was performed with cell monolayers covered with culture 
medium containing 50 nM of redox quenchers (sodium azide, L-histidine and L-cysteine 
from Sigma) just after NPs uptake. 24 h after PDT, the effect of quenchers on cell viability 
was evaluated using MTT viability assay. 
PSs release form NPs in the biological media 
In 2 mL eppendorf, 0.5 mg of NP 7 (bearing 0.145 µmol of PS 1) or 0.5 mg of NP 8 
(bearing 0.108 µmol of PS 2) were dispersed in 1 mL of PBS buffer or RPMI medium. The 
dispersion was placed in laboratory incubator shaker (IKA KS4000) and kept at 37 °C 
without agitation for 4 h and 18 h. After 4 h and 18 h, 0.250 mL of the mixture was mixed 
with 1.250 mL of EtOH and nanoparticles were centrifuged (13300 RPM, RT, 1 min). 
Then, 1 mL of supernatant was mixed with 2 mL of EtOH and UV-Vis was measured. The 
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release of PS form NPs was calculated as follows: release of PS form NPs = mol of release 
PS from NPs / mol of PS in NPs.  
Compering the behavior of nanoparticles after 4 h and 18 h incubations, slow release of PS 
form the silica matrix was observed. Higher release in case of NP 8 was noted then in NP 
7. However, during singlet oxygen study nanoparticles were stable under conditions used 
in the study (Figure SI 4 and Figure SI 5). 
 
Figure SI 15. PSs release form NP 7 and NP 8 in the biological media. Each point 
represents the mean of at least three independent experiments, and has a standard deviation 
lower than 3%. 
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Dark toxicity studies of PSs and NPs 
 
Figure SI 16. Non-dark toxicity of PS 1 and PS 2 (0-10 µM in PBS) determined 24 h after 
treatment using the MTT assay. The percentage of cytotoxicity was calculated relatively to 
control cells (cells incubated with PBS). Data are means ± s.e.m. of at least three 
independent experiments performed in triplicates. 
 
Figure SI 17. Non-dark toxicity of NP 7 (0-0.010 mg/mL, 0-2.89 µM in medium) and NP 
8 (0-0.010 mg/mL, 0-2.15 µM in medium) determined 24 h after treatment using the MTT 
assay. The percentage of cytotoxicity was calculated relatively to control cells (cells 
incubated with RPMI medium). Data are means ± s.e.m. of at least three independent 
experiments performed in triplicates. 
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CHAPTER 3: Nanoparticle-based systems as efficient vehicles to 
transport and deliver photosensitizers into tumor tissues during 
photodynamic therapy in vitro 
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Keywords: Porphyrins, Photosensitizers, Nanosilicas, PDT, Cancer 
Abstract: In recent years, mesoporous silica nanoparticles (MSNPs) have attracted 
tremendous attention in many biomedical applications. One of the fields where smart 
functional nanosystems have found great application is cancer treatment. Here, we present 
nanoparticle-based systems which have been explored as efficient vehicles to transport and 
deliver photosensitizers (PSs) into tumor tissues during photodynamic therapy (PDT). 
Herein we report the preparation, characterization and in vitro studies of distinct shaped 
MSNPs grafted with S-glycoside porphyrins (Pors). The ensuing nanomaterials were fully 
characterized and their properties as new third generation PSs for PDT against two bladder 
cancer cell lines, HT-1376 and UM-UC-3 were examined. 
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Introduction 
In the early 1990s it was discovered a new family of molecular sieves, often called 
M41S.72 In 2001, J. Perez-Pariente et al.177 presented for the first time MCM-41 as a drug 
delivery system by using such materials as hosts and ibuprofen molecules as guests. They 
reported that ibuprofen molecules occupied partially the MCM-41 mesopores and could 
diffuse out of them when the loaded samples were placed in a simulated body fluid. This 
led to new studies on the use of silica nanoparticles (SNPs) as drug delivery systems178,179 
and since then mesoporous silica materials have been explored and used in biomedical 
applications. 
MSNPs in particular have attracted great attention for PDT owing to their biocompatibility, 
large surface area per volume ratio, controllable size formation, hydrophilic surface and 
ability for surface functionalization.42 The possibility of using these systems for tumor 
targeting through adequate surface modification is a key to successful cancer treatment. 
Currently there are nanoparticle-based drug delivery systems which were approved by 
FDA and others are still under clinical trials.153-155 
Despite the fact that researchers established different therapies to treat cancer, for example 
surgery, chemotherapy, radiotherapy and PDT, cancer is still one of the leading cause of 
death in developing countries.180 Nevertheless, PDT has been a very promising and used 
therapy for certain cancer treatments. PDT combines three components: drug, light and 
oxygen. By its own these components do not have any toxic effects on the biological 
systems. They become strongly cytotoxic to the target cells when reactive oxygen species 
(ROS) are produced such as singlet oxygen (1O2), hydroxyl (•HO), peroxyl (•ROO) and 
superoxide anion (•O2-) radicals. This production occurs only when the drug (PS) is in 
contact with molecular oxygen and exposed to light within a wavelength region. In these 
conditions, there is production of radicals via a Type I reaction or, more likely, it takes 
place the production of 1O2 via Type II reaction, which is the major cytotoxic agent 
involved in PDT .132-135  
The lifetime of 1O2 in biological media is very short (10-320 nanoseconds). Hence, the 
photodynamic action in cancer PDT occurs exclusively close to the intracellular location of 
the PS. The lifetime of 1O2 limits its diffusion to more or less 10 to 55 nm in cells158 
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making PDT a selective treatment with less secondary effects than conventional therapies. 
There are three mechanisms in PDT for killing cancer cells: i) ROS directly kill tumor 
cells; ii) damage of the tumor-associated vascular system leading to tumor infarction; iii) 
activation of an immune response against tumor cells. Finally, these three mechanisms can 
influence each other.34 
PDT was approved 20 years ago by the Food and Drug Admnistration (FDA) as a clinical 
protocol for cancer treatment. Still the method has limitations as a general protocol to treat 
any type of cancer. In this context, nanoparticles (NPs) have emerged as promising 
vehicles for use in PDT giving the possibility to successfully improve cancer 
treatment.38,136,137 The application of PSs nanoformulations in PDT can enhance the 
treatment by increasing the biocompatibility of hydrophobic PSs’, their blood circulation 
and selective accumulation in tumor tissues due to enhanced permeability and retention 
effect (EPR).39,40,151  
According to the time of development and specific characteristics of PSs, they have been 
divided in three generations. Most of them are based on a tetrapyrrole structure 
(Pors,10,138,139 chlorins,140-143 bacteriochlorins,144-146 and phthalocyanines147-150). For PDT, 
an ideal PS should be a photostable and water-soluble chemically pure compound. Ideally 
the PS should not exhibit dark toxicity and it should absorb light in the red or deep red 
wavelengths in order to efficiently penetrate tissues. Lastly, PS agent should accumulate in 
the target tissues and rapidly clear from surrounding normal tissues and organs to 
maximize therapy selectivity.158-161,181 
In the design of new PSs for cancer treatment, Pors conjugated to MSNPs surface or 
encapsulated in the silica matrix, appear as a promising third generation PSs. The 
combination of Pors and MSNPs can improve the photophysical properties of Pors. Recent 
studies have demonstrated that by grafting Pors inside or over the surfaces of MSNPs 
could limit the formation of Pors aggregates, low water compatibility and pre-mature 
release of Pors. This method could enhance selectivity for targeted tissues and 
consequently increase the PDT efficiency.93,156,182-186  
Among the variety of examples, Ximing et al.94 prepared an interesting family of Por and 
MSNPs with excellent optical properties and good stability in aqueous solution grafting 
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Por-bridged silsesquioxane into MSNPs. Additionally, Hocine et al.187 incorporated water-
soluble Pors into MSNPs via covalent linkages and then decorated the ensuing hybrids 
with mannose moieties aiming at better cancer cells recognition. In a final step PDT was 
performed on MDA-MB-231 breast cancer cells with great success. Vivero-Escoto et al. 
employed one of the most studied Por, protoporphyrin IX (PpIX), attached through a 
redox-responsive linker to the surface of MSNPs.99 These non-cytotoxic drug delivery 
platforms were able to release PS in reducing conditions present in cancer cells by 
breaking the disulfide bond between NP and PS. Thus, PpIX in monomeric form was 
released and upon light exposure there was HeLa cells destruction due to the 
photogenerated 1O2. On the other hand, Durand et al.103 combined two-photon imaging and 
PDT by preparing mannose-functionalized porous silica-coated magnetic nanoparticles 
with covalently attached Por. After performing PDT on MDA-MB-231 breast cancer cells, 
it was clear that mannose functionalization improved both imaging and PDT due to the 
presence of mannose receptors on breast cancer cells. The same group118 reported cancer 
therapy improvements by exploiting the synergic anticancer effect of two active molecules 
(Por and camptothecin) within a single nanocarrier. They combined targeting, drug 
delivery and PDT by preparing galactose functionalized MSNPs that have been loaded 
with camptothecin and possessing Por at the walls. This enhanced anticancer activity of the 
nanocarriers by improvement of cancer cell death on three cancer cell lines, colorectal 
(HCT-116), pancreatic (Capan-1) and breast cancer (MDA-MB-231). One more example 
how to improve PDT is to combine it with another cancer therapy to get a double action of 
both treatments. Recently, Koichiro Hayashi et al. 128 joined PDT with photothermal 
therapy (PTT) by using a single light source with photostable iodinated silica/Por hybrid 
NPs with heavy-atom effect. They demonstrated that these NPs could be used in PDT/PTT 
combination therapy against multiple myeloma, which is resistant to conventional 
chemotherapy. 
In our research we focused on third generation PSs. Therefore MSNPs bearing S-glycoside 
porphyrins were prepared. As a model PS 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin 
(TPPF20, PS0, Figure 1) was chosen. The results with this PS were promising which 
encouraged us to prepare NPs with ability for cancer cells targeting. Hence, further 
systems have been investigated that include 5,10,15,20-tetrakis(4-1’-thio-glucosyl-2,3,5,6-
tetrafluorophenyl) porphyrin (Glu-Por, PS1, Figure 1) and 5,10,15,20-Tetrakis(4-1’-thio-
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galactosyl-2,3,5,6-tetrafluorophenyl) porphyrin (Gal-Por, PS2, Figure 1). These two PSs 
bear glucose and galactose moieties which are crucial for tumor targeting. Since 
galectin148,188 and glucose148,189,190 proteins are expressed in high levels in cancer cells it is 
important to design PSs with glycol-molecules to obtain successful cancer treatment by 
precise tumor targeting. Thus, PS1 and PS2 were grafted on the surface of MSNPs. As a 
model cancer cells HT-1376 and UM-UC-3 bladder cancer cells, derived from transitional 
cell carcinoma were chosen because both have affinity for galactose and glucose 
molecules. Both carbohydrates express the glyco-binding proteins in different levels: 
glucose transporter (GLUT1) and galactose-binding protein (galectin-1).148 Moreover, in 
order to compare the silica particles’ shape-dependent behavior in HT-1376 and UM-UC-3 
cancer cell lines, sphere-shaped MSNPs and rod-shaped mesoporous silica nanorods 
(MSNRs) were prepared in this research. Finally, the in vitro photodynamic efficacy of the 
new nanomaterials was undertaken with HT-1376 and UM-UC-3 bladder cancer cells. 
 
Figure 1. Structures of PS0, PS1 and PS2.  
Results and discussion 
Preparation and characterization of MSNPs and MSNRs 
In this work PS0, PS1 and PS2 were used as PSs (Figure 1). Firstly, we studied MSNPs 
grafted with commercially available PS0. After satisfactory outcome with these NPs, PS1 
and PS2 were synthesized according to literature procedures described elsewhere.162-166 
There are a number of reports highlighting the potential of glycosylated Pors in PDT 
cancer treatment.162-166 Poor solubility and aggregation of PSs molecules in biological 
media drastically reduce the efficiency of 1O2 photogeneration. Thus, to enhance their 
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stability in aqueous media, the PSs were covalently attached to mesoporous silica matrix 
and deliver to cancer cells as nanovehicles. 
In the beginning of the study, as a model nanomaterial MSNP-PS0 were prepared (Figure 
2). Subsequently, after satisfying evaluation of the 1O2 generation properties of these NPs 
and in vitro studies into two human bladder cancer cell lines, HT-1376 and UM-UC-3, it 
was decided to prepare NPs with better cancer cells recognition. Thus, nanomaterials 
bearing PS with sugar moieties (MSNP-PS1, MSNP-PS2, MSNR-PS1, MSNR-PS2) were 
prepared (Figure 2) and fully characterized. 
MSNPs and MSNRs were prepared under alkaline conditions in which tetraethoxysilane 
(TEOS) was used as the silica precursor and cetyltrimethylammonium bromide (CTAB) 
was used as the structure directing agent (Figure 2).191  
Figure 2. Schematic preparation of nanomaterials grafted with PSs. 
In the first step, different amounts of CTAB (100 mg for MSNP-100, 200 mg for MSNP-
200, 400 mg for MSNP-400, 500 mg for MSNP-500, Figure 2, Table 1) were dissolved in 
water. In this reaction CTAB serves as an organic template for the formation of 
mesoporous silica spheres. After adding ethyl acetate, NH4OH, and TEOS, the solution 
was stirred for 5 min at RT. After that time, additional water was added and pH decreased 
which slower the hydrolysis of TEOS and accelerates the silica condensation. To remove 
the surfactant templates acid extraction was used and NPs were air-dried.  
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The average size of the NPs was estimated by transmission electron microscopy (TEM) ) 
after dispersing the sample in water and drying at ambient temperature. (Figure 3, Table 
1). 
MSNP-100 
 
MSNP-200 
 
MSNP-400 
 
MSNP-500 
 
Figure 3. TEM images of MSNP-100, MSNP-200, MSNP-400 and MSNP-500. 
Nanomaterials’ 
core 
CTAB [mg] Nanomaterials’ Aspect ratio  
(length:width) length [nm] width [nm] 
MSNP-100* 100 117 ± 16 117 ± 16 1 
MSNR-200 200 125 ± 32 65 ± 11 1.9 
MSNR-400 400 134 ± 25 57 ± 12 2.4 
MSNR-500* 500 175 ± 39 36 ± 7 4.9 
Table 1. Size of NPs estimated form TEM. Information on mean size and standard 
deviation was calculated from measuring more than 100 NPs in random fields of TEM 
grids.*NPs used as cores for further experiments.  
The above table (Table 1) indicates that the shape of the particles depends on the CTAB 
concentration in the method of synthesis employed. The higher the concentration of CTAB 
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in the reaction mixture the higher is the aspect ratio of the particles, which is in agreement 
with reports found in the literature.192-194 Moreover, with the growing concentration of 
CTAB, particles become longer and narrower. To compare shape-dependent behavior in 
HT-1376 and UM-UC-3 cancer cell lines, sphere-shaped MSNP-100 (117 ± 16 nm) and 
rod-shaped MSNR-500 (175 ± 39 nm x 36 ± 7 nm) were chosen and named, respectively 
as MSNP and MSNR. Figure 4 shows the TEM images of samples MSNP and MSNR. 
MSNP 
 
MSNR 
 
Figure 4. TEM images showing mesoporous silica particles of distinct shape 
The PSs molecules were grafted on the surfaces of MSNPs and MSNRs using (3-
aminopropyl)triethoxysilane (APTS) as a linker. Firstly, MSNPs and MSNRs were 
functionalized with APTS by dispersing the NPs in water and then adding a solution of 
APTS in ethanol to produce mesoporous silicas with amine terminal groups at the surfaces 
(MSNPs-NH2 and MSNRs-NH2). In the last step of the preparation, the grafting of Por: 
PS0, PS1, and PS2 on the surface of MSNPs-NH2 and MSNRs-NH2 was carried out in 
DMSO at 160 °C, following a method reported in the literature but with minor 
modifications.65 The final hybrid materials were washed with DMSO and EtOH until the 
typical Soret and Q bands of Pors were not observed in the rinsed solvent. The amount of 
Por covalntly attached to NPs was calculated using UV-Vis spectrophotometry by 
subtracting the unreacted Por (from the rinse solvent) from Por taken into rection mixture. 
The highest amount of PS in the mesoporous silica samples was observed for MSNP-PS0 
(26.4 nmol/mg, Table 2), which could be explained by the fact that PS0 is not bearing any 
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sugar molecules. Thus, PS0 has free access to all peripheral fluorine atoms which allows 
easier conjugation with nanomaterials compare to PS1 and PS2. 
Nanomaterial’s 
core 
PS Final hybrid Concentration of PS on the surface of 
NP 
[nmol of PS/mg of NP] 
MSNP PS 0 MSNP-PS0 26.4 
MSNP PS 1 MSNP-PS1 25.0 
MSNP PS 2 MSNP-PS2 19.8 
MSNR PS 1 MSNR-PS1 22.9 
MSNR PS 2 MSNR-PS2 22.6 
Table 2. Concentration of PS on the surface of NP. 
The UV-Vis absorption spectra of all PSs and their nanoformulations were collected after 
dissolving and dispersing the samples in DMSO, respectively (Figures SI 3-5). Pors 
presented Soret bands at 417 nm (PS0), 421 nm (PS1), 421 nm (PS1). Furthermore, all 
NPs showed the typical spectra of a free base Por, with Soret bands at 436 nm (MSNP-
PS0), 431 nm (MSNP-PS1), 436 nm (MSNR-PS1), 435 nm (MSNP-PS2), 438 nm 
(MSNR-PS2). 
The FT-IR was used to evaluate the functionalization of MSNPs and MSNRs with APTS 
(Figure SI 6) and further covalent bonding with Pors (Figure SI 7-9). The aminated NPs 
exhibited the presence of the N−H bending band at ~1600 cm-1 and broad bands in the 
2800 to 3800 cm-1 region, corresponding to stretching vibrations of primary amines, which 
indicated that the amino groups were bound onto the NPs surface.195-197 After covalent 
functionalization with Pors, a new band appeared at ~1590 cm-1 corresponding to the C=C 
vibrational modes of Pors. The band at ~1700 cm-1 could be attributed to the bending 
vibration of the C=N of the Por ring. Hence, the FT-IR spectra provided evidence that Pors 
molecules have been covalently attached to the surface of MSNPs and MSNRs. 
Singlet oxygen generation study 
The ability of the functionalized nanomaterials to generate 1O2 was determined by an 
indirect chemical method in which 1,3-diphenylisobenzofuran (DPBF) acts as 1O2 
quencher. DPBF has an absorption maximum at 415 nm and forms a colorless 
endoperoxide product when it reacts with singlet oxygen (Figure SI 1). In this method the 
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ability of PSs or NPs to generate 1O2 is measured by following the DPBF absorption decay 
at its maximum absorption (415 nm). 
In this study, all solutions or suspensions for analysis were prepared in DMSO and stirred 
under irradiation for defined time intervals, at room temperature. Probes were exposed to 
light of a 300 W halogen lamp. Incident light was filtered through orange filter to take out 
light below 530 nm. 5,10,15,20-tetrakis-phenyl-21,23-H-porphyrin (TPP) was used as a 
reference compound. Under these conditions all MSNPs and MSNRs tested were 
photostable (Table SI 1). 
The 1O2 generation was determined for all nanoformulations (MSNP-PS0, MSNP-PS1, 
MSNR-PS1, MSNP-PS2, MSNR-PS2) and the corresponding PSs (PS0, PS1 and PS2) 
(Figure 5). The free PS0, PS1 and PS2 were tested at concentrations of 0.5 µM and new 
nanomaterials were tested at concentrations of PS: 0.5 µM and 2.5 µM (Figure 5). Free PS 
1 and PS 2 oxidized DPBF in the same way. PS0 oxidized DPBF slightly less than PSs 
bearing sugar moieties. 
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Figure 5. 1O2 generation by PS0, PS1, PS2 and its corresponding NPs (MSNP-PS0, 
MSNP-PS1, MSNP-PS2 and MSNR-PS1, MSNR-PS2) were each point represents the 
mean of at least three independent experiments, and has a standard deviation lower than 3 
%. Concentrations indicated for all nanomaterials refer to the equivalent concentration of 
non-immobilized porphyrins. 
From the 1O2 generation study we can observe that free PS0, PS1 and PS2 oxidized DPBF 
almost in the same way (Figure 5, Figure 6). 
0.2
0.4
0.6
0.8
1
0 5 10 15 20 25 30
DP
BF
 d
ep
le
tio
n
time [min]
PS1 vs MSNP-PS1 vs MSNR-PS1
DPBF, 50 uM
TPP, 0.5 uM
PS1, 0.5 uM
MSNP-PS1, 0.5 uM
MSNP-PS1, 2.5 uM
MSNR-PS1 0.5 uM
MSNR-PS1, 2.5 uM
0.2
0.4
0.6
0.8
1
0 5 10 15 20 25 30
DP
BF
 d
ep
le
tio
n
time [min]
PS2 vs MSNP-PS2 vs MSNP-PS2
DPBF, 50 uM
TPP, 0.5 uM
PS2, 0.5 uM
MSNP-PS2, 0.5 uM
MSNP-PS2, 2.5 uM
MSNR-PS2, 0.5 uM
MSNR-PS2, 2.5 uM
81 
 
 
Figure 6. DPBF absorbance depletion in the presence of PS0, PS1, PS2 and its 
corresponding NPs (MSNP-PS0, MSNP-PS1, MSNP-PS2 and MSNR-PS1, MSNR-PS2) 
at different concentrations (0.5 and 2.5 µM) after 30 min of irradiation. Concentrations 
indicated for all nanomaterials refer to the equivalent concentration of non-immobilized 
Pors. Data are the mean value of at least three independent experiments. 
DPBF kinetic decay was similar in all sphere-shaped particles (MSNP-PS0, MSNP-PS1, 
MSNP-PS2). After 30 min of irradiation these nanoformulations were able to reduce about 
50 % of DPBF with 2.5 µM of PS concentration. All sphere-shaped particles produced 
more 1O2 than rod-shaped particles (Figure 6). Which means that MSNPs should be more 
efficient than MSNRs in terms of cancer treatment in PDT. This could be due to the fact 
that in case of smaller NPs (NPs with smaller aspect ratio) oxygen can penetrate better 
their pores and 1O2 has shorter way to go out from nanoformulation than in bigger NPs. 
Thus, MSNPs are more effective in 1O2  production than MSNRs while corresponding free 
Pors (PS1 and PS2) are producing the same amount of 1O2 under the equal experimental 
conditions. 
In vitro studies 
In vitro studies were carried out into two human bladder cancer cell lines, HT-1376 and 
UM-UC-3. These cell lines are suitable in vitro cancer models for the evaluation of new 
glyco-porphyrinoids, since they express the glyco-binding proteins (glucose transporter, 
GLUT1 and galactose-binding protein, galectin-1) in different levels.148 Previous studies 
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have proved that these two proteins have a key role on the uptake and finally on the 
phototoxicity of a galactodendritic phthalocyanine.148 HT-1376 cancer cells express 
GLUT1 in higher levels when compared with UM-UC-3 and the former expresses galectin-
1 in higher levels when compared with HT-1376.148 
Cellular uptake of PSs and its nanoformulations 
Preliminary uptake studies were performed using free PS (PS0, PS1, PS2). Bladder cancer 
cells were incubated in dark conditions with increasing concentrations of PS (0, 2.5, 5, 10 
µM prepared in PBS, maximum 0.5% DMSO v/v) for 4 h. Fluorescence spectroscopy 
studies demonstrated that PS1 accumulation was higher in HT-1376 than in UM-UC-3 
cancer cells (Figure 7). On the other hand, the uptake of PS0 and PS2 was higher in UM-
UC-3 than in HT-1376 cancer cells. Accumulation of PS0 was much lower in both cancer 
cells than accumulation of PS bearing sugar groups. This can be explained by the fact that 
these cells express the glyco-binding proteins and PS0 is free Por without any sugar units. 
Thus, the uptake of PS1 and PS2 should be higher as compared with PS0. In the case of 
PS1 and PS2, the uptake was dependent on the concentration of the PS and cell line. 
Among the studied PSs, the highest uptake was observed for PS1. 10 µM of gluco-PS1 
was almost two times better accumulated in both cancer cell lines as compared to galacto-
PS2. This could be caused by the fact that both HT-1376 and UM-UC-3 cancer cells have 
higher levels of glucose receptors when compared with galactose receptors. Thus, the 
presence of sugar moieties is important during the uptake of PSs by both cancer cells. 
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Figure 7. Intracellular uptake of PS0, PS1, PS2 (0-10 µM in PBS) by UM-UC-3 and HT-
1376 bladder cancer cells. Cells were incubated with PS for 4 h and uptake was determined 
by fluorescence spectroscopy. Data are means ± s.e.m. of at least three independent 
experiments performed in triplicates. 
Next, the uptake of MSNP-PS0, MSNP-PS1, MSNP-PS2, MSNR-PS1 and MSNR-PS2 
was evaluated by fluorescence spectroscopy (Figure 8) after incubating UM-UC-3 and 
HT-1376 bladder cancer cells in dark condition with different concentrations of new NPs 
(0-20 µM of PS). 
 
Figure 8. Intracellular overnight uptake of MSNP-PS0, MSNP-PS1, MSNR-PS1, MSNP-
PS2 and MSNR-PS2 (0-20 µM of PS in RPMI medium) by UM-UC-3 and HT-1376 
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bladder cancer cells. Data are means ± s.e.m. of at least three independent experiments 
performed in triplicates. 
Uptake studies were performed by incubating cancer cells with PS nanoformulations 
overnight. When the cells were incubated overnight with medium containing NPs solutions 
there was uptake dependent on the concentration of the NPs but not on the cell line (which 
was observed with free PSs). Interestingly, the uptake of MSNP-PS1 was almost three 
times lower when compared with the uptake of MSNR-PS1. On the other hand, the uptake 
of MSNP-PS2 was negligible higher than MSNR-P2. This could be explained by different 
concentrations of PS on the surface of NPs (Table 3). 
NP name Concentration of PS on 
the surface of NP 
[nmol of PS/mg of NP] 
Uptake in HT-1376 
[nmol PS/mg 
protein]* 
Uptake in UM-UC-3 
[nmol PS/mg 
protein]* 
MSNP-PS1 25.0 9.8 18.7 
MSNR-PS1 22.9 20.5 51.8 
MSNR-PS2 22.6 38.3 60.1 
MSNP-PS2 19.8 39.9 70.6 
Table 3. Comparison between concentration of PS on the surface of NPs and its uptake 
behavior (*the uptake is presented for 20 µM of PS into each experiment). Concentrations 
indicated for all nanomaterials refer to the equivalent concentration of non-immobilized 
porphyrins. 
The comparison between the amount of PS on the surface of NPs and the corresponding 
cell uptake value shows that there is an inverse trend relating this data, i.e. as the amount of 
PS per mg of NP increases there is a decrease on the cell uptake (Table 3, Figure 9). In the 
present uptake studies, although the same amount of PS was used the nanoformulations 
had different amounts of PS on their surfaces, thus different amounts of NPs were used in 
the experiments. When the concentration of PS on the NPs’ surface was higher, the smaller 
was the amount of NPs (in mg) taken into experiment resulting in a smaller uptake. In 
conclusion, the uptake depends not only on the concentration of PS on the surface of NPs 
but also on the amount of NPs (in mg or numbers of NPs). 
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Figure 9. Schematic representation of suggested uptake process in cancer cells which is in 
inverse proportion to the concentration of PS on the surface of NP per mg of NP. The same 
mechanism is proposed for MSNPs and MSNRs. 
Furthermore, it was observed that the uptake of all new nanoformulations was higher in 
UM-UC-3 cancer cells (with high level of galectin-1) when compared with HT-1376 cells 
(with high level of GLUT1 protein). This could be a result of better delivery process of 
MSNPs and MSNRs in UM-UC-3 than in HT-1376 cells. Interestingly, MSNP-PS0 was 
the only sample that accumulated better in both cancer cell lines than the corresponding 
non-immobilized Por (Figures 7, 8). The uptake of these sphere-shaped particles was ten 
times better in cancer cells when compared to free PS0. MSNP-PS0 (117 ± 16 nm) had the 
tendency to accumulate in tumor tissue much more than smaller molecules of PS0. This 
selective accumulation in tumor tissues could be related with EPR effect in which certain 
size particles accumulate in tumor tissue much better than in normal tissues.39,40,151 
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Dark toxicity and phototoxicity 
The dark toxicity of PS0, PS1, PS2 and its corresponding nanoformulations (MSNP-PS0, 
MSNP-PS1, MSNP-PS2 and MSNR-PS1, MSNR-PS2) was evaluated using the well-
known MTT assay (Figures SI 10, 11) in UM-UC-3 and HT-1376 bladder cancer cells. 
This colorimetric assay uses the ability of living bladder cancer cells to reduce yellow 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT), to a purple formazan. 
Thus, it is a straightforward tool to determine the cell metabolic activity. After overnight 
incubation of cancer cells (in dark) with NPs (0-20 µM of PS in RPMI medium) or 4 h 
incubation with PSs (0-10 µM in PBS buffer), none of the PSs or new NPs induced dark 
toxicity in cancer cells. This outcome is crucial in the PDT concept, since the ideal 
therapeutic drug should not show cytotoxicity until photoactivation. 
 
Figure 10. Phototoxicity of PS0, PS1, PS2 (0-10 µM) determined 24 h after PDT 
treatment using the MTT assay. The percentage of cytotoxicity was calculated relatively to 
control cells (cells incubated with PBS and then irradiated). Data are means ± s.e.m. of at 
least three independent experiments performed in triplicates. 
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Figure 11. Phototoxicity of MSNP-PS0, MSNP-PS1, MSNP-PS2 and MSNR-PS1, 
MSNR-PS2 (0-20 µM of PS) determined 24 h after PDT treatment using the MTT assay. 
The percentage of cytotoxicity was calculated relatively to control cells (cells incubated 
with medium and then irradiated). Data are means ± s.e.m. of at least three independent 
experiments performed in triplicates.  
Following the confirmation of the uptake and non-dark toxicity of PSs and their new 
nanoformulations in UM-UC-3 and HT-1376 bladder cancer cells, their toxicity after light 
irradiation was evaluated using the MTT assay (Figures 10, 11). In this study UM-UC-3 
and HT-1376 bladder cancer cells were incubated with PSs (0-10 µM in PBS buffer) for 4 
h or with NPs (0-20 µM of PS in RPMI medium) overnight, and then irradiated with an 
optical fiber emitting white light for 40 min (12 mW/cm2). No cytotoxicity was observed 
in the untreated (cells incubated in the absence of NP) sham irradiated cells.  
When the cells were incubated for 4 h in PBS containing PSs (0-10 µM in PBS buffer) 
there was phototoxicity dependent on the concentration of the PSs (Figure 10). PS1 and 
PS2, led to  higher phototoxicity in both cancer cells than the PS0 sample. This could be 
explained by the fact that these two PSs with sugar units presented much better uptake 
properties in HT-1376 and UM-UC-3 cancer cells compared to PS0. PS1 and PS2 
presented slightly higher phototoxicity in UM-UC-3 cancer cells than in HT-1376 cancer 
cells. 
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After UM-UC-3 and HT-1376 bladder cancer cells were incubated overnight in medium 
with NPs (0-20 µM of PS) there was phototoxicity dependent on the concentration of the 
PSs (Figure 11). Although all new NPs induced photoxicity in UM-UC-3 and HT-1376 
bladder cancer cells in a concentration-dependent manner, the overall phototoxicity was 
higher with PSs than with NP formulations. 
In general, the phototoxicity was higher with MSNPs than with MSNRs (Table 4). All 
NPs presented higher phototoxicity in UM-UC-3 cancer cells than in HT-1376 cancer 
cells. Which could be the result of better uptake observed in these cell lines (Figure 8). 
Although the best uptake was observed for MSNP-PS2 in both, UM-UC-3 and HT-1376 
bladder cancer cells, in case of photoxicity, MSNP-PS1 with the lowest uptake results 
presented the highest photoxicity in the same cancer cells lines (Table 4). 
NP name Concentration 
of PS on the 
surface of NP 
[nmol of 
PS/mg of NP] 
Uptake in Phototoxicity in 
HT-1376 
[nmol PS/mg 
protein]* 
UM-UC-3 
[nmol PS/mg 
protein]* 
HT-1376 
[%]** 
UM-UC-3 
[%]** 
MSNP-PS1 25.0 9.8 18.7 62.8 44.9 
MSNR-PS1 22.9 20.5 51.8 78.1 54.8 
MSNR-PS2 22.6 38.3 60.1 74.9 57.2 
MSNP-PS2 19.8 39.9 70.6 64.5 55.2 
Table 4. Relation between concentration of PS on the surface of NPs and its uptake 
behavior with phototoxicity results (*the uptake is presented for 20 µM of PS into each 
experiment, **the phototoxicity is presented after 30 min of light irriadiation). 
There is a clear relation between the uptake behavior and phototoxicity results. For all 
nanovehicles, the higher uptake was observed in UM-UC-3 than in HT-1376 cancer cells. 
The same behavior was spotted during phototoxicity studies. The phototoxicity was higher 
in UM-UC-3 than in HT-1376 cancer cells. 
To improve the phototoxicity of all new nanovehicles, second light irradiation treatment 
could increase in vitro photodynamic efficacy as it was already demonstrated in the 
literature.174 In the period between single and repeated irradiation NPs could accumulate in 
cancer cells which could enhance phototoxicity in both cancer cell lines.  
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Conclusions 
In summary, sphere-shaped mesoporous silica particles and rod-shaped mesoporous silica 
particles grafted with S-glycoside Pors were successfully prepared and characterized. All 
novel nanomaterials were able to produce 1O2 hence in vitro studies with two human 
bladder cancer cell lines, HT-1376 and UM-UC-3, were performed. 
When HT-1376 and UM-UC-3 cells were incubated overnight with medium containing 
NPs solutions there was an uptake dependent on the concentration of the NPs but not on 
the cell line which was observed with free PSs. Furthermore, it was noted that the uptake 
of all new nanoformulations was higher in UM-UC-3 cancer cells (with high level of 
galectin-1) when compared with HT-1376 cells (with high level of GLUT1 protein). From 
these results, it can be concluded that the cells uptake depends not only on the 
concentration of PS on the surface of NPs but also on the amount of NPs employed (in mg 
or numbers of NPs). Comparing the concentration of PS on the surface of NPs with uptake 
studies, the uptake is in inverse proportion to concentration of PS per mg of NP. Although 
MSNP-PS0 presented the lowest phototoxicity among all tested NPs samples, these NPs 
were the only which accumulated better in both cancer cell lines than the corresponding 
non-immobilized porphyrin (PS0). The uptake of these sphere-shaped particles was ten 
times better in cancer cells when compared to free PS0. 
None of the PSs or new NPs induced dark toxicity in cancer cells. Despite the fact that all 
new NPs induced photoxicity in UM-UC-3 and HT-1376 bladder cancer cells in a 
concentration-dependent manner, the overall phototoxicity was higher with free PSs than 
with NPs. In general the phototoxicity was higher with MSNPs than with MSNRs. For all 
nanovehicles higher uptake was observed in UM-UC-3 than in HT-1376 cancer cells. The 
same behavior was noted during phototoxicity studies. The phototoxicity was higher in 
UM-UC-3 than in HT-1376 cancer cells. 
The resulting new nanocarriers were fully described and their properties as new third 
generation PSs for PDT against two bladder cancer cell lines, HT-1376 and UMUC-3 were 
proved. The final results showed that our new nano-systems could be successfully use in 
PDT of bladder cancer which is the fourth most commonly diagnosed cancer180 with the 
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high rate of recurrence. Further advances towards improving therapeutic efficacy of PDT 
treatment by these NPs are under research. 
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Supplementary Information 
Nanoparticle-based systems as efficient vehicles to transport and deliver 
photosensitizers into tumor tissues during photodynamic therapy in vitro 
Experimental section 
General methods 
Absorption spectra were recorded using a JASCO V-660 UV-Visible Spectrophotometer. 
FT-IR spectra were recorded in KBr pellets using GRASEBY SPECAC or with Cary 630 
FT-IR Spectrometer. The irradiation system used to determine the production of 1O2 was 
the Newport irradiation system, consisting on a 300 W halogen lamp, FSQ-OG530 color 
glass filter for wavelengths <530 nm and magnetic stirrer. The irradiation system used to 
determine the phototoxicity during biological experiments was a Lumacare system, model 
LC-122, consisting on a 250 W halogen lamp coupled to an optical fiber (with a cutoff 
filter for wavelengths <540 nm). The radiation power was measured with a potentiometer 
bright Spectra Physics, model 407A and the sensor of the same brand, model 407A-2. 
Transmission electron microscopy (TEM) images were obtained using a JEOL JEM1010 
transmission electron microscope operating at an acceleration voltage of 100 kV. 
All reagents were obtained from commercial sources and were used without further 
purification steps. Reverse phase column chromatography was carried out on Waters Sep-
Pak C18 35 cm3 cartridges. Analytical thin layer chromatography (TLC) was carried out on 
pre-coated silica gel sheets (Merck, 60, 0.2 mm). 
Synthesis of NPs 
Synthesis of MSNPs and MSNRs 
MSNPs and MSNRs were prepared after slight modification of the method presented in 
the literature.191 In a first step, CTAB (100 mg for MSNP-100, 200 mg for MSNP-200, 
400 mg for MSNP-400, 500 mg for MSNP-500,) was dissolved in water (100 mL) in 
Erlenmeyer flask equipped with magnetic bar. Next, to the above solution ethyl acetate 
(0.88 mL) and NH4OH (30%, 2.7 mL) were subsequently added. In the end, TEOS (500 
µL) was added and the solution was stirred for 5 min at RT. After that, 100 mL of water 
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was added to slower the hydrolysis of TEOS and accelerates the silica condensation. After 
24 h of stirring at RT, NPs were filtered and washed with EtOH. To remove the surfactant 
templates, nanoparticles were redispersed in 100 mL of ethanol/acetic acid (glacial) 
mixture (95/5, v/v) and the mixture was stirred for 30 minutes. In the end, nanoparticles 
were washed with EtOH and air-dried. 
MSNPs’ and MSNRs’ functionalization with APTS 
To the suspension of 30 mg of MSNPs or MSNRs in 2.5 mL H2O, 158 µL of APTS in 750 
µL of EtOH was added. After adjusting the pH to 7 by adding 0.2 M HCl (2.25 mL) the 
reaction was stirred at RT for 24 h. MSNPs-NH2 and MSNRs-NH2 were washed with 
EtOH and air-dried. 
Grafting of PS on the surface of MSNPs-NH2 and MSNRs-NH2 
The grafting of porphyrins PS0, PS1, and PS2 on the nanomaterials MSNPs-NH2 and 
MSNRs-NH2 was carried out in DMSO at 160 °C according to the literature, with minor 
modifications.65 35 mg of MSNPs-NH2 or MSNPs-NH2 were resuspended in DMSO (1 
mL). A solution of PS (2.38 µmol) in DMSO (4 mL) was added to that suspension and the 
resulting mixture was magnetically stirred for 96 h at 160 °C. After that time, a red hybrid 
materials were obtained. The resulting hybrid materials were washed with DMSO and 
EtOH until no Soret and Q bands were observed in the rinse solvent and air-dried. The 
amount of unreacted porphyrin was calculated by UV-Vis spectrophotometry. 
Singlet oxygen generation study 
Singlet oxygen (1O2) was determined by a chemical method using 1,3-
diphenylisobenzofuran (DPBF). DPBF has an absorption maximum at 415 nm, thus it is 
possible to follow the ability of the NPs to generate 1O2 by measuring the DPBF absorption 
decay, at this wavelength.  
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Figure SI 1. Reaction occurring during singlet oxygen generation study. The yellow-
colored DPBF reacts with 1O2 in [4+2] cycloaddition reaction, being oxidized to the 
colorless o-benzoylbenzene. 
The solutions were irradiated at RT under magnetic stirring and light from a 300 W 
halogen lamp with a cutoff filter for wavelengths <530 nm (Figure SI 2). 5,10,15,20-
tetrakis-phenyl-21,23-H-porphyrin (TPP) was used as a reference compound. 
 
Figure SI 2. Equipment used for singlet oxygen generation study. 
TPP (0.5 μM), PS0 (0.5 μM), PS1 (0.5 μM), PS2 (0.5 μM), MSNP-PS0 (0.5 μM, 2.5 μM 
of PS), MSNP-PS1 (0.5 μM, 2.5 μM of PS), MSNR-PS1 (2.5 μM of PS), MSNP-PS2 (0.5 
μM, 2.5 μM of PS) or MSNR-PS2 (2.5 μM of PS) were placed into 3 mL cuvette which 
contained DMSO. Then DPBF (50 μM) in DMSO was added (total volume in cuvette 3 
mL). The final solutions were irradiated at RT and under gentle magnetic stirring and light 
from a 300 W halogen lamp (with a cut off filter for wavelengths <530 nm). The 
breakdown of DPBF was monitored by measuring the decrease in absorbance at 415 nm at 
pre-established irradiation intervals. The results were expressed by plotting the DPBF 
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depletion against the irradiation time. The depletion of DPBF was calculated as follows: 
DPBF depletion = Abs1/Abs0. Abs0 and Abs1 are the absorbance values at 415 nm before 
and after irradiation, respectively. 
Photostability of NPs during singlet oxygen generation study 
Photostability studies were carried out in the same conditions of irradiation of the singlet 
oxygen studies but without DPBF. The results are presented in ratio calculated by the ratio 
of residual absorbance at 415 nm (DPBF), 418 nm (TPP), 417 nm (PS0), 421 nm (PS1), 
421 nm (PS1), 436 nm (MSNP-PS0), 431 nm (MSNP-PS1), 436 nm (MSNR-PS1), 435 
nm (MSNP-PS2), 438 nm (MSNR-PS2) at different periods of time and absorbance 
before irradiation. Each point represents the mean of at least three independent 
experiments, and has a standard deviation lower than 2%. Nanoparticles were stable during 
singlet oxygen study. 
Compounds/NPs Irradiation time (min) 
 0 1 2 5 10 20 30 
DPBF 1 0.99 0.99 0.99 0.98 0.97 0.97 
TPP 1 0.99 0.99 0.99 0.99 0.99 0.99 
PS0 1 0.99 0.99 0.99 0.99 0.99 0.99 
PS1 1 0.99 0.99 0.98 0.98 0.98 0.98 
PS2 1 0.99 0.99 0.99 0.99 0.99 0.98 
MSNP-PS0 1 0.99 0.98 0.97 0.95 0.93 0.92 
MSNP-PS1 1 0.99 0.98 0.96 0.93 0.91 0.89 
MSNP-PS2 1 0.99 0.99 0.98 0.97 0.95 0.94 
MSNR-PS1 1 0.99 0.98 0.97 0.96 0.94 0.93 
MSNR-PS2 1 0.99 0.98 0.97 0.97 0.97 0.94 
Table SI 1. Photostability of NPs during singlet oxygen study. 
Characterization of NPs 
UV-Vis spectra of PSs, MSNPs and MSNRs 
UV-Vis absorption spectra were collected after dispersion of MSNPs and MSNRs in 
DMSO or after dissolving PS0, PS1 and PS2 in DMSO. Concentrations indicated for all 
nanomaterials refer to the equivalent concentration of non-immobilized porphyrins. 
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Figure SI 3. UV-Vis spectra of PS0 and corresponding MSNP-PS0. 
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Figure SI 4. UV-Vis spectra of PS1 and corresponding MSNP-PS1, MSNR-PS1. 
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Figure SI 5. UV-Vis spectra of PS2 and corresponding MSNP-PS2, MSNR-PS2. 
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FT-IR spectra of PSs, MSNPs and MSNRs 
 
Figure SI 6. FT-IR spectra of MSNP, MSNP-NH2, MSNR and MSNR-NH2. 
 
Figure SI 7. FT-IR spectra of PS0 and corresponding MSNP-PS0. 
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Figure SI 8. FT-IR spectra of PS1 and corresponding MSNP-PS1, MSNR-PS1. 
 
Figure SI 9. FT-IR spectra of PS2 and corresponding MSNP-PS2, MSNR-PS2. 
In vitro assays 
Cells culture 
Human bladder cancer cell lines UM-UC-3 and HT-1376 derived from high-grade 
transitional cell carcinoma were obtained from the American Type Culture Collection 
(ATCC®, Manassas, VA, USA). Cells were cultured in Roswell Park Memorial Institute 
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(RPMI)-1640 medium (Sigma) supplemented with 2 g.L-1 sodium bicarbonate (Sigma), 2 
mM L-glutamine (Sigma), 10% (v/v) of heat-inactivated Fetal Bovine Serum (FBS; Life 
Technologies, Carlsbad, CA, USA) and antibiotic/antimicotic containing 100 units.mL-1 
penicillin, 100 µg.mL-1 streptomycin and 0.25 µg.mL-1 amphotericin B (Sigma). UM-
UC-3 and HT-1376 cells were seeded at a density of 1.5 x 104 in 96-well culture plates 
(Orange Scientific, Braine-l'Alleud, Belgium). 24 hours after plating, cells were overnight 
incubated with different concentrations of NPs (0-20 µM of PS in RPMI medium) in the 
dark. 
Cellular uptake of NPs 
After incubation with NPs in the dark, UM-UC-3 and HT-1376 cells were washed with 
PBS buffer and mechanically scrapped in 1% (m/v) sodium dodecyl sulfate (SDS; Sigma) 
in PBS buffer at pH 7.0. NPs intracellular concentration was determined by 
spectrofluorimetry using a microplate reader (Synergy HT, Biotek, Winooski, VT, USA) 
with the excitation filter (set at 360±40 nm) and emission filter (645±40 nm). Results were 
normalized for protein concentration (determined by bicinchoninic acid reagent; Pierce, 
Rockford, IL, USA). 
PDT treatments on cells 
Photodynamic irradiation was carried out in fresh culture medium, in the absence of NPs, 
covering UM-UC-3 and HT-1376 cell monolayers with RPMI medium and exposing them 
to white light delivered by the illumination system LC-122 LumaCare at 12 mW/cm-2 for 
40 min. As a control, sham-irradiated cells were used. These cells were kept in the dark for 
the same durations and under the same conditions as the irradiated cells. In all trials, 
triplicate wells were settled under each experimental condition, and each experiment was 
repeated at least three times. 
MTT assay 
MTT assay was used to determine cell metabolic activity after NPs incubation in the dark, 
irradiation, or both after 24 h. This colorimetric assay is measuring the ability of bladder 
cancer cells to reduce yellow 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide (MTT, Sigma), to a purple formazan on a microplate reader (Synergy HT). The 
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results are expressed in percentage of control (i.e. optical density of formazan from cells 
not exposed to NPs).  
Dark toxicity studies of PSs, MSNPs and MSNRs 
 
Figure SI 10. Non-dark toxicity of PS 1, PS2 and PS3 (0-10 µM) determined 24 h after 
treatment using the MTT assay. The percentage of cytotoxicity was calculated relatively to 
control cells (cells incubated with PBS). Data are means ± s.e.m. of at least three 
independent experiments performed in triplicates. 
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Figure SI 11. Non-dark toxicity of MSNP-PS0, MSNP-PS1, MSNP-PS2 and MSNR-
PS1, MSNR-PS2 (0-20 µM of PS) determined 24 h after treatment using the MTT assay. 
The percentage of cytotoxicity was calculated relatively to control cells (cells incubated 
with medium). Data are means ± s.e.m. of at least three independent experiments 
performed in triplicates. 
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CHAPTER 4: Silica nanoformulations of phosphonated-phthalocyanines 
as novel anticancer agents for photodynamic therapy 
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Abstract: This research reports the combination of amorphous silica nanoparticles (SNPs) 
with phosphonated phthalocyanines (Pcs) which presents very interesting properties for 
photodynamic therapy (PDT). NPs were synthetized after slight modification of the reverse 
microemulsion method. The new materials presented high ability to generate singlet 
oxygen (1O2) after light irradiation. Thus, the in vitro photodynamic properties of 
phosphonate-Pc SNPs were determined using human bladder cancer epithelial cell line 
UM-UC-3. Obtained results could be very promising for cancer treatment in PDT. 
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Introduction 
Silica materials are ‘‘generally recognized as safe’’ (GRAS) by the US Food and Drug 
Administration (FDA).198 Together with facile silica nanoparticles’ preparation and broad 
range of their potential future applications, these new nanomaterials play an important role 
in current cancer research.  
Cancer is one of the biggest health problem for humans. On nanomedicine, one of the 
therapies that has explored this concept is cancer PDT, an alternative method to the 
conventional cancer treatment options, including chemotherapy, radiotherapy and 
surgery.199-202 This technique combines three components: drug, visible or near-infrared 
light and oxygen. None of them are toxic for the biological systems by its own. Only when 
the drug, called photosensitizer (PS) or photosensitizing agent, is in contact with molecular 
oxygen and exposed to proper light, can produce reactive oxygen species (ROS), which are 
strongly cytotoxic to the target cancer cells132-135.  
Based on the time of development and specific characteristics of PSs, they have been 
divided in three generations. The first generation PSs are the hematoporphyrins (Hp) to 
which belongs the first FDA approved PDT sensitizer, Photofrin® (porfimer sodium).35 
These first generation PSs are complex mixture of oligomers and their intensity of light 
absorption at the maximum wavelength is quite low. Second generation photosensitizers 
have lower skin phototoxicity, higher absorption in the red region of the visible spectrum 
and higher purity compare to their first generation precursors. They refers to porphyrins, 
chlorins, pheophorbides, bacteriopheophorbides, texaphyrins and phthalocyanines. A third 
generation PSs arose to improve selectivity, bioavailability and therapeutic properties of 
the previously mentioned PSs. They are first and second generation PSs conjugated to 
biomolecules, like proteins, peptides and also nanocarriers.203 
Although this straightforward therapy was approved 20 years ago as a clinical protocol for 
cancer treatment,204 there are still several limitations to use it as a general protocol to treat 
all cancer types. In the context of these limitations, nanoparticles (NPs) have recently 
emerged as promising vehicles for PDT.38,136,137 Among others NPs, a number of 
applications of SNPs take advantage of their properties as protecting shells for sensitive 
compounds and magnetic cores.152 
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Pcs are synthetic porphyrin analogues, consisting of four isoindole units linked together 
through nitrogen atoms.205 Very often Psc are hydrophobic species and undergo self-
aggregation in aqueous solutions, which drastically reduces their photosensitizing 
efficiency. Nevertheless, Pcs can be conjugated to SNPs surface or encapsulated in the 
silica matrix, improving their photophysical properties, as recently described by Lei Ren et 
al.106 They proved that the preparation of zinc Pc-loaded mesoporous silica nanoparticles 
(ZnPc-MSNPs) can help to maintain ZnPc molecules as a monomers and enhance PDT 
effect. ZnPc in monomeric state has higher production of 1O2 thus acts as a better PS than 
in aggregate state.106 After intravenous injection of these NPs in tumor-bearing mice 
followed by light exposure, these nanoplatforms exhibited great PDT efficacy. On the 
other hand, to avoid aggregation of ZnPc in aqueous environments, Zhao et al. 107 loaded 
ZnPc into the nanochannels of adamantane-functionalized MSNPs. To examine the PDT 
efficiency of this new nanomaterial, the MTT cell viability assay on HeLa cancer cell lines 
was performed. Comparing new NPs with free ZnPc in solution, more effective apoptosis 
effect by the hybrid after light irradiation was observed. These ZnPc loaded NPs exhibited 
stability in aqueous solution and low cytotoxicity in the dark. Additionally, the preparation 
of amorphous SNPs of mono-PEGylated ZnPc and its in vitro photodynamic activity was 
described by Dennis K. P. Ng et al.109 The photodynamic activity of these systems toward 
HepG2 human hepatocarcinoma cells was studied with great success. These NPs were 
promising PDT agents, because of their uniform size, stability in aqueous media, high 1O2 
generation efficiency and high cellular uptake. 
Nanovehicles could combine not only therapeutic effect but also other features crucial for 
cancer treatment. Hence, Ren et al. 110 combined distance-dependent metal-enhanced 
fluorescence (MEF) and metal-enhanced 1O2 generation phenomenon by attaching tetra-
substituted carboxyl phthalocyaninatealuminum(II) (AlC4Pc) to silica-coated gold 
nanorods (AuNRs) core-shell nanoparticles. It was observed that the fluorescence intensity 
and 1O2 generation varied with the thickness difference of silica shell. Thus, amorphous 
silica shell could serve as a spacer layer between the AuNRs and AlC4Pc to get an 
optimum fluorescence enhancement effect. Moreover, thanks to silica matrix Zheng et 
al.113 were able to fuse tree features: magnetic resonance imaging and fluorescence 
imaging, cell targeting and PDT. The core of the NPs was made from a single Fe3O4 NP 
encapsulated in fluorescent dyes co-doped nonporous silica. This core was covered by 
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ordered mesoporous silica containing PSs. Folic acid was used as fluorescence imaging 
agent which was covalently incorporated into the silica core. As PS, AlC4Pc was chosen 
and it was covalently linked to mesoporous silica to avoid the degradation of PS in 
biological environments, and overcome their premature release. Again, these NPs 
presented much higher 1O2 production than the same amount of free AlC4Pc in solution 
which suggested that these nanovehicles act as nanoreactors to facilitate the photo-
oxidation reaction. Juan L. Vivero-Escoto et al.126 took the advantage of encapsulating and 
attaching drugs on SNPs surface which occurred with the development of multi drug 
delivery systems for combination chemotherapy and PDT by loading MSNPs with 
cisplatin and aluminum chloride Pc (AlClPc). The combination of both AlClPc and 
cisplatin compounds in the same MSNPs produced higher cytotoxic effect against human 
cervical cancer HeLa cells in comparison to the control MSNPs loaded with AlClPc and 
MSNPs loaded with cisplatin. This is another good example of SNPs which simultaneously 
carry PS and anticancer drug for combination PDT and chemotherapy to treat cancer. With 
this procedure they were able to enhance cancer therapy in the synergic anticancer effect of 
two active molecules in the same nanocarrier. 
Encouraged by all examples of improving photophysical properties of Pcs by integrating 
PS with SNPs, we decided to combine amorphous SNPs with phosphonate-Pcs, previously 
described by some of us as novel anticancer agents for PDT.206 Herein, Pc was 
encapsulated into SNPs or covalently attached to the surface of SNPs. As it was mentioned 
before one of the drawbacks of Pcs is their tendency to form aggregates in biological 
media. This aggregation phenomenon decreases the ROS production and thus 
phototoxicity. Encapsulation of Pc into SNPs or covalently attaching on the surface of 
SNPs could increase the specificity and the target release/accumulation of the PS. 39,40,151 
Results and discussion 
Preparation of Pc 
Phosphonate Pc was synthetized according to the procedure described by Venkatramaiah, 
N. et al.206 in the literature. The synthetic route is presented below (Figure 1). 
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Figure 1. Synthetic route for the preparation of phosphonate-functionalized Pc (Pc). 
First, 4,5-dichlorophthalonitrile (1) and triethylphosphite reacted under microwave 
conditions at 230 °C for 45 min in a palladium-catalyzed cross coupling reaction, yielding 
tetraethyl(4,5-dicyano-1,2-phenylene)bisphosphonate (2). Then, cyclotetramerization of 2 
took place in a sealed glass tube under a nitrogen atmosphere with ZnCl2, DBU and EtOH 
at 120 °C for 12 h. In the end, final green-coloured Pc was obtained after the hydrolysis of 
the protected octaphosphonate groups of Pc 3, using for that trimethylsilyl bromide 
(TMSBr) in dry CH2Cl2 at room temperature. 
Preparation and characterization of SNPs 
SNPs (NP-0, Figure 2) were synthetized after slight modification of the reverse 
microemulsion method described by Aurélien Auger et al.207 First, a quaternary 
microemulsion was prepared by mixing Triton X-100, 1-octanol and cyclohexane at RT. 
Then, water, NH4OH and TEOS were added. The mixture was stirred for 24 h at RT and 
after that time ethanol was added to disrupt the inverse micelles. NPs were collected by 
centrifugation and washed with water and ethanol. 
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Figure 2. Schematic illustration of the preparation of SNPs (NP-0). 
Next, Pc was encapsulated into SNPs (NP-1 and NP-2, Figure 3) using the same method 
except that Pc was present in the reaction mixture. In case of NP-1, to the mixture of 
Triton X-100, 1-octanol and cyclohexane, the solution of Pc in water was added. In the 
end, NH4OH and TEOS were added. On the other hand, NP-2 were synthetized after slight 
modification of the above approach. The mixture of Triton X-100, 1-octanol and 
cyclohexane was first prepared in the same way and then the solution of Pc in the mixture 
of water and NH4OH was added. In the last step, TEOS was added. The water/NH4OH 
mixture promoted a better solubility of the Pc in the reaction mixture, enhancing the 
concentration of PS into final NPs. 
 
Figure 3. Schematic illustration of the preparation of NP-1 and NP-2. 
In the last case, phosphonate-Pc was covalently attached to the surface of SNPs (NP-3, 
Figure 4). These NPs were synthetized by combining solution of Pc in DMSO with NP-0 
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dispersed in 1,2,4-trichlorobenzene. The mixture was stirred for 24 h at 200 °C under 
nitrogen atmosphere and then NPs were collected by centrifugation and carefully washed. 
Having the covalent bond between NP-0 and Pc could avoid premature leakage of PS in 
biological environment. 
 
Figure 4. Schematic illustration of the hybrid Pc-SNP NP-3. 
The average size of all NPs was measured by transmission electron microscopy (TEM) 
after drying the sample and dynamic light scattering (DLS) as a dispersion in water 
(Figures SI 2-10). The difference in particle sizes measured by TEM (NP-0, 35.14 ± 2.22 
nm; NP-1, 35.67 ± 3.27 nm; NP-2, 36.92 ± 3.71 nm; 36.00 ± 1.88 nm) and DLS (NP-0, 
56.65 nm; NP-1, 55.36 nm; NP-2, 55.23 nm; NP-3, 88.63 nm) presented the frequent 
difference between the size measured by TEM and the mean hydrodynamic diameter  by 
DLS. Presented NPs are regular in terms of the size and shape and have uniform size 
distribution. Moreover, these NPs have very good size for passive targeting to tumor 
tissues.170 
The UV-Vis absorption spectra of NP-0, NP-1, NP-2 and NP-3 were collected after 
dispersing, 0.150 mg of each NPs in 3 mL of EtOH (Figure SI 11). It is clear that NP-1, 
NP-2 and NP-3 show the typical broad bands of a free Pc. FT-IR spectra of Pc and all new 
NPs were also recorded (Figure SI 12) and proved the presence of PS in the SNPs. 
The amount of encapsulated Pc inside SNPs or covalently attached to the SNPs was 
calculated by UV-Vis spectrophotometry. The final NPs were washed with the appropriate 
solvent until no typical Soret and Q bands were observed in the rinse solvent. NP-1 
(0.0874 µmol Pc/mg) and NP-2 (0.0812 µmol Pc/mg) have almost the same concentration 
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of PS per mg of final material. The lower concentration of PS was observed for NP-3 
(0.0683 µmol Pc/mg). 
Singlet oxygen generation study 
In PDT treatment, when the PS is in contact with molecular oxygen and exposed to proper 
light it can produce ROS that are strongly cytotoxic to the cancer cells. Thus, after NPs’ 
preparation and their full characterization an indirect chemical method was used to 
determined 1O2 generation. As a quencher diphenylisobenzofuran (DPBF) with absorption 
maximum at 415 nm was employed. By measuring the DPBF absorption decay at this 
wavelength it was possible to follow the ability of the NPs to generate 1O2. In 1O2 study, 
the solutions contained Pc 1 (0.5 μM), NP-1 (0.5 mg, 14.57 μM of Pc), NP-2 (0.5 mg, 
13.53 μM of Pc) or NP-3 (0.5 mg, 11.38 μM of Pc) were compared (Figure 5).  
 
Figure 5. Photo-oxidation of DPBF (50 μM) in DMF:H2O (9:1, by volume) with or 
without NPs (NP-1: 0.5 mg, 14.57 μM of Pc; NP-2: 0.5 mg, 13.53 μM of Pc, or NP-3: 0.5 
mg, 11.38 μM of Pc) and Pc (0.5 μM), after irradiation with red light (620–750 nm) at a 
fluence rate of 10 mW/cm2 for different periods of time (0-50 min). The DPBF absorbance 
was recorded at 415 nm. Each point represents the mean of at least three independent 
experiments, and has a standard deviation lower than 3%. 
From the above graph it is clearly visible that both NPs, NP-1 and NP-2 are producing 
almost the same amount of singlet oxygen. NP-3 are generating very small amount of 1O2. 
This may be explained by the fact that these NPs have the tendency to aggregate in the 
0
0.2
0.4
0.6
0.8
1
0 10 20 30 40 50
DP
BF
 d
ep
le
tio
n
time [min]
DPBF, 50 uM
Pc, 0.5 uM
NP-1, 0.5 mg, 14.57 uM
NP-2, 0.5 mg, 13.53 uM
NP-3, 0.5 mg, 11.38 uM
112 
 
water-based solution what was observed during DLS measurement. The difference in NP-3 
sizes measured by TEM (36.00 ± 1.88 nm) and DLS (88.63 nm) showed not only the 
common difference between the mean hydrodynamic diameter and the size measured by 
TEM but also the predisposition to form small aggregates. These aggregates could make 
difficulties for oxygen and 1O2 to travel freely in the experimental environment.  
It is also very important to point out the different morphologies of the NPs used in the 1O2 
tests. NP-1 and NP-2 do not have any covalent bonds between SNPs and Pc thus PS could 
be released during experiments. On the contrary, Pc is permanently attached to SNPs 
through covalent bond in NP-3.  
It was crucial to check the release of Pc from all phosphonate-Pc SNPs (Figure 6). The 
conditions of experiment were the same as for 1O2 generation study, but under dark. The 
Pc release was determined by following the absorbance spectra after gentle stirring at 
ambient temperature. The results were displayed as follows: Pc release [%] = Absorbance 
at given time (Abst)/ initial Absorbance (Abs0). 
 
Figure 6. Release of Pc from NPs in DMF:H2O (9:1, by volume) after gentle stirring in the 
dark at ambient temperature for different periods of time (0-50 min). The results are 
presented in percentage calculated by the ratio of residual absorbance 680 nm (Abs of Pc) 
at different periods of time and initial absorbance. Each point represents the mean of at 
least three independent experiments, and has a standard deviation lower than 3%. 
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Figure 6 shows that Pc was slowly released from NP-1 and NP-2 but not from NP-3. This 
could explain the high production of 1O2 by NP-1 and NP-2. It is important to remember 
that small production of 1O2 by NP-3 is not only due to the absence of Pc release but most 
probably because of NPs’ aggregates were formed during experiment. The high ability of 
these new hybrid NPs to generate 1O2 after light irradiation lead us to determine their 
photocytotoxicity in human bladder cancer cells. 
In vitro studies 
In vitro studies were carried out into UM-UC-3 cancer cell line. Previous studies have 
demonstrated that this Pc, containing phosphonic acid groups, exhibit dual anticancer 
functionality, inhibiting the urokinase plasminogen activator and efficiently generating 1O2 
inducing (photo)toxicity on human bladder cancer epithelial cells UM-UC-3.206 
Cellular uptake of PS and its nanoformulations 
Preliminary uptake studies were performed with NP-1, NP-2, NP-3 (Figure 7) and free Pc. 
Bladder cancer cells were incubated in darkness with increasing concentrations of PS (0-25 
µM) for 2 h and with NPs (NP-1: 0-0.01 mg/mL, 0-0.874 µM of Pc; NP-2: 0-0.01 mg/mL, 
0-0.812 µM of Pc; NP-3: 0-0.01 mg/mL, 0-0.683µM of Pc) prepared in RPMI medium, 
maximum 0.5% DMSO v/v) overnight. 
Figure 7. Intracellular 2 h uptake of free Pc (0-25 µM),206 and overnight uptake of NP-1, 
(0-0.01 mg/mL, 0-0.874 µM of Pc in RPMI medium), NP-2 (0-0.01 mg/mL, 0-0.812 µM 
of Pc in RPMI medium), NP-3 (0-0.01 mg/mL, 0-0.683µM of Pc in RPMI medium) by 
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UM-UC-3 bladder cancer cells. Data are means ± s.e.m. of at least three independent 
experiments performed in triplicates. 
When the cells were incubated overnight with RPMI medium containing NPs solutions 
there was uptake dependent on the concentration of the NPs. In all cases NPs presented 
higher uptake than free Pc. This could be due to the tendency of particles of certain size to 
accumulate in tumor tissue much more than they do in normal tissue which is called 
enhanced permeability and retention effect. Although NP-1 (0.0874 µmol Pc/mg) and NP-
2 (0.0812 µmol Pc/mg) have almost the same concentration of PS per mg of final material, 
NP-2 presented higher uptake than NP-1. Interestingly, the lowest concentration of PS in 
NP-3 (0.0683µmol Pc/mg) not interfered with the highest uptake of NP-3 among all new 
materials tested. The uptake of NP-3 was about two times highest than NP-1 and NP-2. In 
NP-3, Pc is permanently attached to the SNPs through covalent bonds and is located on the 
surface of NPs. Presence of Pc on the surface of SNPs could enhance cellular uptake of 
NP-3. It was already proven that presence of phosphonic acid groups in the periphery of Pc 
(Pc, Figure 1) rather than protected groups in octaphosphonate Pc (3, Figure 1) could 
increase its accumulation inside bladder cancer cells with consequently higher 
phototoxicity.206  
Dark toxicity and phototoxicity 
The dark toxicity of Pc, NP-0, NP-1, NP-2 or NP-3 in UM-UC-3 bladder cancer cells was 
evaluated using the well-known MTT assay (Figure SI 13). MTT assay is a colorimetric 
assay which use the ability of living bladder cancer cells to reduce yellow 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT), to a purple formazan. 
After overnight incubation of cancer cells (in dark) with NPs (NP-1: 0-0.01 mg/mL, 0-
0.874 µM of Pc; NP-2: 0-0.01 mg/mL, 0-0.812 µM of Pc; NP-3: 0-0.01 mg/mL, 0-
0.683µM of Pc) in RPMI medium or 2 h incubation with PS (0-25 µM in PBS buffer), 
none of the PS or new NPs induced dark toxicity in cancer cells (Figure SI 13). Non-dark 
toxicity is crucial in the PDT concept in which the therapeutic drug has to have no toxicity 
until it is activated by light. 
After confirming the uptake and non-dark toxicity of Pc and their new NP formulations in 
UM-UC-3 bladder cancer cells, their toxicity after light irradiation was evaluated using the 
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MTT assay (Figure 8). UM-UC-3 bladder cancer cells were incubated for 2 h with Pc (0-
25 µM in PBS buffer) or overnight with NPs (0-20 µM in RPMI medium) and then 
irradiated with an optical fiber emitting white light for 40 min (12 mW/cm2). No 
cytotoxicity was observed in the untreated (cells incubated in the absence of NP) sham 
irradiated cells. 
  
Figure 8. Phototoxicity of Pc (0-25 µM)206 and NP-1, NP-2, NP-3 (0-20 µM of Pc) 
determined 24 h after PDT treatment using the MTT assay. The percentage of cytotoxicity 
was calculated relatively to control cells (cells incubated with RPMI medium and then 
irradiated). Data are means ± s.e.m. of at least three independent experiments performed in 
triplicates. 
Phototoxicity of Pc determined after PDT treatment was higher compared with 
corresponding NP formulations. NP-0 do not present any phototoxicity against cancer cells 
(Figure SI 14). Other NPs induced photoxicity in UM-UC-3 bladder cancer cells in a 
concentration-dependent manner. MTT assay showed that after PDT treatment 
phototoxicity of NP-1 and NP-2 was almost the same. Remembering outcome from singlet 
oxygen generation studies (Figure 5) and cellular uptake studies (Figure 7), this result was 
not surprising. Maybe in UM-UC-3 bladder cancer cells resistant to therapy, a second light 
irradiation treatment could enhanced in vitro photodynamic efficacy as it was described 
before.174 In the period between single and repeated irradiation NPs could accumulate in 
cancer cells which could enhanced phototoxicity in UM-UC-3 cancer cells. 
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Remarkable, NP-3 led to a significantly higher phototoxicity on UM-UC-3 cells compared 
to NP-1 and NP-2. Although in 1O2 generation studies these NPs produced very poor 
amount of 1O2, in biological condition they appeared as the most efficient among all tested 
NPs. The reason of this result could be because the uptake of these NPs was higher due to 
the presence of Pc on the surface of NPs compare to the NP-1 and NP-2 (Figure 7). Also 
during 1O2 generation studies the NPs were dispersed into the mixture of DMF:H2O (9:1, 
by volume). This could cause the aggregation of NP-3 because of the presence of Pc on the 
surface of SNPs. In UM-UC-3 cells the environment was different and it could enhance the 
NPs internalization into the target organelles. 
Conclusions 
In summary, novel NPs encapsulating Pc (NP-1, NP-2) or covalently appended Pc (NP-3) 
were prepared and evaluated as photoactive nanoformulations in cancer PDT. These NPs 
had uniform size distribution and were regular in terms of size and shape with a very good 
size for passive targeting to tumor tissues. 1O2 generation studies showed that NP-1 and 
NP-2 are producing almost the same amount of 1O2 whereas NP-3 were generating poor 
amount of 1O2. In vitro studies were carried out in UM-UC-3 cancer cell line. After 
incubation of cancer cells (in dark) with NPs or PS, none of the PS or new NPs induced 
dark toxicity in UM-UC-3 cancer cells. The uptake of NP-3 in these cells was about two 
times higher than NP-1 and NP-2. In NP-3, the cellular uptake could be enhance by 
presence of Pc on the surface of NPs. In the last experiment NP-3 led to a significantly 
higher phototoxicity on UM-UC-3 cells compared to NP-1 and NP-2. Even though these 
new nanocarriers had lower pototoxicity efficiency compered to non-immobilized Pc, they 
offer an alternative route to enhance PDT by their surface modification to get even higher 
selectivity/recognition and uptake by cancer cells. The discussed studies showed that these 
NPs could be used as efficient nanoplatform agents for cancer PDT. Further advances 
towards in vitro and in vivo protocols to increase therapeutic efficacy of PDT treatments 
are strongly encouraged. 
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Supplementary Information 
Silica nanoformulations of phosphonated-phthalocyanines as novel anticancer agents 
for photodynamic therapy 
Experimental section 
 
General methods 
Absorption spectra were recorded using a Shimadzu UV-2501-PC. FT-IR spectra were 
recorded in KBr pellets using Spectrophotometer Bruker IFS 66V. The irradiation system 
used to determine the production of 1O2 and the phototoxicity during in vitro experiments 
was a Lumacare source, model LC-122, consisting on a 250 W halogen lamp coupled to an 
optical fiber (with a cutoff filter for wavelengths <540 nm). The fluence rate was measured 
with an energy meter (Coherent Field MaxII-Top) combined with a Coherent Power Sens 
PS19Q energy sensor. The Dynamic light scattering (DLS) measurements were taken by 
Zetasizer Nano ZS from Malvern Instruments. Transmission electron microscopy (TEM) 
images were obtained using a Hitachi H-9000 transmission electron microscope operating 
at an acceleration voltage of 300 kV and JEOL 2200FS transmission electronmicroscope 
operating at an acceleration voltage of 200 kV.  
All reagents were obtained from commercial sources and were used without further 
purification steps. Analytical thin layer chromatography (TLC) was carried out on pre-
coated silica gel sheets (Merck, 60, 0.2 mm). 
Synthesis of Pc 
Pc was synthetized according to procedure described by Venkatramaiah, N. et al.206  
Preparation of NPs 
Preparation of NP-0 
NPs were synthetized after slight modification of the reverse microemulsion method 
described by Aurélien Auger et al.207 First, a quaternary microemulsion was prepared by 
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mixing Triton X-100 (4.2 mL), 1-octanol (4.0 mL) and cyclohexane (18.8 mL) at RT. 
Then, water (1.2 mL), NH4OH (25%, 0.240 mL) and TEOS (0.250 mL) were added. The 
mixture was stirred for 24 h at RT and after that time ethanol (100 mL) was added to 
disrupted the inverse micelles. NPs were collected by centrifugation and washed with 
water and ethanol.  
Preparation of NP-1 
NPs were synthetized after slight modification of the reverse microemulsion method 
described by Auger A. et al.207 First, a quaternary microemulsion was prepared by mixing 
Triton X-100 (2.1 mL), 1-octanol (2.0 mL) and cyclohexane (9.4 mL) at RT. Then, the 
solution of Pc (5.6 mg) in water (0.600 mL) was added. In the end, NH4OH (25%, 0.120 
mL) and TEOS (0.125 mL) were added. The mixture was stirred for 24 h at RT and after 
that time ethanol (100 mL) was added to disrupted the inverse micelles. NPs were 
collected by centrifugation and washed with water and ethanol. 
Preparation of NP-2 
NPs were synthetized after slight modification of the reverse microemulsion method 
described by Auger A. et al.207 First, a quaternary microemulsion was prepared by mixing 
Triton X-100 (2.1 mL), 1-octanol (2.0 mL) and cyclohexane (9.4 mL) at RT. Then, the 
solution of Pc (5.6 mg) in water (0.600 mL) and NH4OH (25%, 0.120 mL) was added. In 
the last step TEOS (0.125 mL) was added. The mixture was stirred for 24 h at RT and after 
that time ethanol (100 mL) was added to disrupted the inverse micelles. NPs were 
collected by centrifugation and washed with water and ethanol. 
Preparation of NP-3 
NPs were synthetized by combining solution of Pc (1 mg) in DMSO (0.500 mL) with 
SNPs (NP-0, 10 mg) dispersed in 1,2,4-trichlorobenzene (1.2 mL). The mixture was stirred 
for 24 h at 200 °C under nitrogen atmosphere. After that time NPs were collected by 
centrifugation and washed with DMSO, water and ethanol. 
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Singlet oxygen generation study 
Singlet oxygen (1O2) was determined by a chemical method using 1,3-
diphenylisobenzofuran (DPBF). DPBF has an absorption maximum at 415 nm, thus it is 
possible to follow the ability of the NPs to generate 1O2 by measuring the DPBF absorption 
decay, at this wavelength. The solutions were irradiated at RT and under magnetic stirring, 
with optical fiber (with a cutoff filter for wavelengths <540 nm) at a fluence rate of 10 
mW/cm2. 
 
Figure SI 1. Reaction of DPBF with 1O2. 
Pc (0.5 μM), NP-1 (0.5 mg, 14.57 μM of Pc), NP-2 (0.5 mg, 13.53 μM of Pc) or NP-3 (0.5 
mg, 11.38 μM of Pc) were placed into 3 mL cuvette which contained solution of 
DMF:H2O (9:1, by volume). Then, DPBF (50 μM) in solution of DMF:H2O was added 
(total volume in cuvette 3 mL). The final solutions were irradiated at RT and under gentle 
magnetic stirring, with optical fiber (with a cut off filter for wavelengths <540 nm) at a 
fluence rate of 10 mW/cm2 for different periods of time (0-50 min). The breakdown of 
DPBF was monitored by measuring the decrease in absorbance at 415 nm at pre-
established irradiation intervals. The results were expressed by plotting the DPBF 
depletion against the irradiation time. The depletion of DPBF was calculated as follows:  
DPBF depletion = Absorbance at given time of irradiation (Abst)/ Absorbance before 
irradiation (Abs0) 
Release of Pc from NPs 
The release of the phosphonate phthalocyanine Pc from NPs was determined by following 
its absorbance spectra after gentle stirring in the dark at ambient temperature. In all 
experiments, 0.5 mg of NPs (NP-1, NP-2, NP-3) were dispersed in 3 mL of DMF:H2O 
(9:1, by volume). The dispersions were placed into cuvettes and were stirred in the dark 
room during 50 min. The results were calculated as follows: 
Photostability [%] = Absorbance at given time (Abst)/ initial Absorbance (Abs0) 
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Characterization of NPs 
Size of NPs form TEM and DLS 
NP name Average size of NPs 
calculated in ImageJ form 
TEM images [nm]* 
Average size of NPs from 
DLS measurement [nm] 
NP-0 35.14 ± 2.22 56.65 
NP-1 35.67 ± 3.27 55.36 
NP-2 36.92 ± 3.71 55.23 
NP-3 36.00 ± 1.88 88.63 
Figure SI 2. Size of NPs form TEM and DLS. *Information on mean size and standard 
deviation was calculated from measuring more than 100 nanoparticles in random fields of 
TEM grids. 
TEM 
  
Figure SI 3. TEM images of NP-0. 
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Figure SI 4. TEM images of NP-1. 
  
Figure SI 5. TEM images of NP-2. 
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Figure SI 6. TEM images of NP-3. 
DLS 
 
Figure SI 7. DLS size distribution of NP-0 in water. 
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Figure SI 8. DLS size distribution of NP-1 in water. 
 
Figure SI 9. DLS size distribution of NP-2 in water. 
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Figure SI 10. DLS size distribution of NP-3 in water. 
UV-Vis 
 
Figure SI 11. UV-Vis absorption spectra of all new NPs in EtOH. UV-Vis absorption 
spectra were collected after dispersion of 0.150 mg of NPs in 3 mL of EtOH. 
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FT-IR 
 
Figure SI 12. FT-IR spectra of Pc and all new NPs. 
In vitro assays 
Cells culture 
Human bladder cancer cell line UM-UC-3 derived from high-grade transitional cell 
carcinoma was obtained from the American Type Culture Collection (ATCC®, Manassas, 
VA, USA). Cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium 
(Sigma) supplemented with 2 g.L-1 sodium bicarbonate (Sigma), 2 mM L-glutamine 
(Sigma), 10% (v/v) of heat-inactivated Fetal Bovine Serum (FBS; Life Technologies, 
Carlsbad, CA, USA) and antibiotic/antimicotic containing 100 units.mL-1 penicillin, 100 
µg.mL-1 streptomycin and 0.25 µg.mL-1 amphotericin B (Sigma). UM-UC-3 cells were 
seeded at a density of 1.5 x 104 in 96-well culture plates (Orange Scientific, Braine-
l'Alleud, Belgium). 24 hours after plating, cells were overnight incubated with different 
concentrations of NPs (0-0.010 mg/mL or 0-20 µM) in the dark. 
Cellular uptake of NPs 
After incubation with NPs in the dark, UM-UC-3 cells were washed with PBS buffer and 
mechanically scrapped in 1% (m/v) sodium dodecyl sulfate (SDS; Sigma) in PBS buffer at 
pH 7.0. NPs intracellular concentration was determined by spectrofluorimetry using a 
5001000150020002500300035004000
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Typhoon FLA 9000 imager (GE Healthcare) with a 100-μm spot resolution and 300 V. The 
excitation and emission wavelengths were set at 635 nm (red LD laser) and LPR (665LP). 
The results were normalized for protein concentration (determined by bicinchoninic acid 
reagent; Pierce, Rockford, IL, USA). 
PDT treatments on cells 
Photodynamic irradiation was carried out in fresh culture medium, in the absence of NPs, 
covering UM-UC-3 cell monolayers with RPMI medium and exposing them to red light 
delivered by the illumination system LC-122 LumaCare at 12 mW/cm-2 for 40 min. As a 
control, sham-irradiated cells were used. These cells were kept in the dark for the same 
durations and under the same conditions as the irradiated cells. In all trials, triplicate wells 
were settled under each experimental condition, and each experiment was repeated at least 
three times. 
MTT assay 
MTT assay was used to determine cell metabolic activity after NPs incubation in the dark, 
irradiation, or both after 24 h treatments. This colorimetric assay is measuring the ability of 
bladder cancer cells to reduce yellow 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT, Sigma), to a purple formazan on a microplate reader (Synergy 
HT). The results are expressed in percentage of control (i.e. optical density of formazan 
from cells not exposed to NPs). 
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Dark toxicity studies of Pc, NP-0, NP-1, NP-2 and NP-3 
  
Figure SI 13. Non-dark toxicity of Pc (0-25 µM)206 and NP-0 (0-0.01 mg/mL, 0 µM of 
Pc), NP-1 (0-0.01 mg/mL, 0-0.874 µM of Pc), NP-2 (0-0.01 mg/mL, 0-0.812 µM of Pc), 
NP-3 (0-0.01 mg/mL, 0-0.683µM of Pc) determined 24 h after treatment using the MTT 
assay. The percentage of cytotoxicity was calculated relatively to control cells (cells 
incubated with RPMI medium). Data are means ± s.e.m. of at least three independent 
experiments performed in triplicates. 
Phototoxicity studies of NP-0 
 
Figure SI 14. Phototoxicity of NP-0 (0-0.01 mg/mL) determined 24 h after PDT treatment 
using the MTT assay. The percentage of cytotoxicity was calculated relatively to control 
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cells (cells incubated with medium and then irradiated). Data are means ± s.e.m. of at least 
three independent experiments performed in triplicates. 
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